

COVID-19 Disease Map, a computational knowledge repository of SARS-CoV-2 virus-host interaction mechanisms

Marek Ostaszewski¹, Anna Niarakis^{2,3}, Alexander Mazein¹, Inna Kuperstein^{4,5}, Robert Phair⁶, Aurelio Orta-Resendiz^{7,8}, Vidisha Singh², Sara Sadat Aghamiri⁹, Marcio Luis Acencio¹, Enrico Glaab¹, Andreas Ruepp¹⁰, Gisela Fobo¹⁰, Corinna Montrone¹⁰, Barbara Brauner¹⁰, Goar Frischman¹⁰, Luis Cristóbal Monraz Gómez^{4,5}, Julia Somers¹¹, Matti Hoch¹², Shailendra Kumar Gupta¹², Julia Scheel¹², Hanna Borlinghaus¹³, Tobias Czauderna¹⁴, Falk Schreiber^{13,14}, Arnau Montagud¹⁵, Miguel Ponce de Leon¹⁵, Akira Funahashi¹⁶, Yusuke Hiki¹⁶, Noriko Hiroi^{16,17}, Takahiro G. Yamada¹⁶, Andreas Dräger^{18,19,20}, Alina Renz¹⁸, Muhammad Naveez^{12,21}, Zsolt Bocskei²², Francesco Messina^{23,24}, Daniela Börnigen²⁵, Liam Fergusson²⁶, Marta Conti²⁷, Marius Rameil²⁷, Vanessa Nakonecni²⁷, Jakob Vanhoefer²⁷, Leonard Schmiester^{28,29}, Muying Wang³⁰, Emily E. Ackerman³⁰, Jason Shoemaker^{30,31}, Jeremy Zucker³², Kristie Oxford³², Jeremy Teuton³², Ebru Kocakaya³³, Gökçe Yağmur Summak³³, Kristina Hanspers³⁴, Martina Kutmon^{35,36}, Susan Coort³⁵, Lars Eijssen^{35,37}, Friederike Ehrhart^{35,37}, D. A. B. Rex³⁸, Denise Slenter³⁵, Marvin Martens³⁵, Robin Haw³⁹, Bijay Jassal³⁹, Lisa Matthews⁴⁰, Marija Orlic-Milacic³⁹, Andrea Senff Ribeiro^{39,41}, Karen Rothfels³⁹, Veronica Shamovsky⁴², Ralf Stephan³⁹, Cristoffer Sevilla⁴³, Thawfeek Varusai⁴³, Jean-Marie Ravel^{44,45}, Rupsha Fraser⁴⁶, Vera Ortseifen⁴⁷, Silvia Marchesi⁴⁸, Piotr Gawron^{1,49}, Ewa Smula¹, Laurent Heirendt¹, Venkata Satagopam¹, Guanming Wu⁵⁰, Anders Riutta³⁴, Martin Golebiewski⁵¹, Stuart Owen⁵², Carole Goble⁵², Xiaoming Hu⁵¹, Rupert W. Overall^{53,54}, Dieter Maier⁵⁵, Angela Bauch⁵⁵, Benjamin M. Gyori⁵⁶, John A. Bachman⁵⁶, Carlos Vega¹, Valentin Grouès¹, Miguel Vazquez¹⁵, Pablo Porras⁴³, Luana Licata⁵⁷, Marta Iannuccelli⁵⁷, Francesca Sacco⁵⁷, Anastasia Nesterova⁵⁸, Anton Yuryev⁵⁸, Anita de Waard⁵⁹, Denes Turei⁶⁰, Augustin Luna^{61,62}, Ozgun Babur⁶³, Sylvain Soliman³, Alberto Valdeolivas⁶⁰, Marina Esteban-Medina^{64,65}, Maria Peña-Chilet^{64,65,66}, Tomáš Helikar⁶⁷, Bhanwar Lal Puniya⁶⁷, Dezso Modos^{68,69}, Agatha Treveil^{68,69}, Marton Olbei^{68,69}, Bertrand De Meulder⁷⁰, Aurélien Dugourd^{60,71}, Aurelien Naldi³, Vincent Noel⁴, Laurence Calzone^{4,5}, Chris Sander^{61,62}, Emek Demir¹¹, Tamas Korcsmaros^{68,69}, Tom C. Freeman⁷², Franck Augé²², Jacques S. Beckmann⁷³, Jan Hasenauer^{28,74}, Olaf Wolkenhauer¹², Egon L. Wilighagen³⁵, Alexander R. Pico³⁴, Chris T. Evelo^{35,36}, Marc E. Gillespie^{43,75}, Lincoln D. Stein³⁹, Henning Hermjakob⁴³, Peter D'Eustachio⁴⁰, Julio Saez-Rodriguez⁶⁰, Joaquin Dopazo^{64,65,66,76}, Alfonso Valencia⁷⁷, Hiroaki Kitano^{78,79}, Emmanuel Barillot^{4,5}, Charles Auffray⁷⁰, Rudi Balling¹, Reinhard Schneider¹, **and the COVID-19 Disease Map Community**⁸⁰

1. Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg
2. Department of Biology, Univ. Evry, University of Paris-Saclay, GenHotel, Genopole, 91025, Evry, France
3. Lifeware Group, Inria Saclay-Ile de France, Palaiseau 91120, France
4. Institut Curie, PSL Research University, Paris, France. INSERM, U900, Paris, France.
5. MINES ParisTech, PSL Research University, Paris, France.
6. Integrative Bioinformatics, Inc., 346 Paul Ave, Mountain View, CA, USA
7. Institut Pasteur, HIV, Inflammation and Persistence Unit, Paris, France
8. Bio Sorbonne Paris Cité, Université de Paris, Paris, France
9. Inserm- Institut national de la santé et de la recherche médicale. Saint-Louis Hospital 1 avenue Claude Vellefaux Pavillon Bazin 75475 Paris
10. Institute of Experimental Genetics (IEG), Helmholtz Zentrum München-German Research Center for Environmental Health (GmbH), Ingolstädter Landstraße 1, D-85764 Neuherberg, Germany
11. Oregon Health & Sciences University; Department of Molecular and Medical Genetics; 3222 SW Research Drive, Portland, Oregon, U.S.A 97239
12. Department of Systems Biology and Bioinformatics, University of Rostock, 18051 Rostock, Germany
13. Department of Computer and Information Science, University of Konstanz, Konstanz, Germany
14. Monash University, Faculty of Information Technology, Department of Human-Centred Computing, Wellington Rd, Clayton VIC 3800, Australia
15. Barcelona Supercomputing Center (BSC), Barcelona, Spain
16. Keio University, Department of Biosciences and Informatics, 3-14-1 Hiyoshi Kouhoku-ku Yokohama Japan 223-8522
17. Sanyo-Onoda City University, Faculty of Pharmaceutical Sciences, University St.1-1-1, Yamaguchi, Japan 756-0884
18. Computational Systems Biology of Infections and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), University of Tübingen, 72076 Tübingen, Germany
19. Department of Computer Science, University of Tübingen, 72076 Tübingen, Germany
20. German Center for Infection Research (DZIF), partner site Tübingen, Germany
21. Riga Technical University, Institute of Applied Computer Systems, 1 Kalku Street, LV-1658 Riga, Latvia
22. Sanofi R&D, Translational Sciences, 1 av Pierre Brosolette 91395 Chilly-Mazarin France
23. Dipartimento di Epidemiologia Ricerca Pre-Clinica e Diagnostica Avanzata, National Institute for Infectious Diseases 'Lazzaro Spallanzani' I.R.C.C.S., Rome, Italy
24. COVID 19 INMI Network Medicine for IDs Study Group, National Institute for Infectious Diseases 'Lazzaro Spallanzani' I.R.C.C.S., Rome, Italy
25. Bioinformatics Core Facility, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
26. The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG
27. Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany
28. Helmholtz Zentrum München - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany
29. Technische Universität München, Center for Mathematics, Chair of Mathematical Modeling of Biological Systems, 85748 Garching, Germany
30. Department of Chemical and Petroleum Engineering, University of Pittsburgh
31. Department of Computational and Systems Biology, University of Pittsburgh
32. Pacific Northwest National Laboratory, 902 Battelle Boulevard, Richland, WA, US
33. Ankara University, Stem Cell Institute, Ceyhan Atif Kansu St. No: 169 06520 Cevizlidere, Ankara, Turkey
34. Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158, US
35. Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands
36. Maastricht Centre for Systems Biology (MaCSBio), Maastricht University, Maastricht, The Netherlands
37. Maastricht University Medical Centre, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
38. Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India
39. Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3
40. NYU Grossman School of Medicine, New York NY 10016, US
41. Universidade Federal do Paraná, Brasil
42. NYU Langone Medical Center, New York, USA
43. EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD

44. University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France
45. Laboratoire de génétique médicale, CHRU Nancy, Nancy, France
46. The University of Edinburgh, Queen's Medical Research Institute. 47 Little France Crescent, Edinburgh, EH16 4TJ
47. Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitätsstraße 27, 33615 Bielefeld, Germany
48. Uppsala University, Sweden
49. Poznan University of Technology, Institute of Computing Science, ul. Piotrowo 2, 60-965 Poznan, Poland
50. Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA
51. Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg, Germany
52. The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK
53. German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany
54. Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, Fetscherstraße 105, 01307 Dresden, Germany
55. Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany
56. Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA, US
57. University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy
58. Elsevier, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103, US
59. Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465, US
60. Heidelberg University, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany
61. cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, US
62. Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, US
63. University of Massachusetts Boston, Computer Science Department, 100 William T. Morrissey Blvd, Boston, MA 02125, US
64. Clinical Bioinformatics Area, Fundación Progreso y Salud (FPS), Hospital Virgen del Rocío, Sevilla, 41013, Spain
65. Computational Systems Medicine group, Institute of Biomedicine of Seville (IBIS). Hospital Virgen del Rocío, Sevilla 41013, Spain
66. Bioinformatics in Rare Diseases (BiER). Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocío, 41013, Sevilla, Spain
67. University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, US
68. Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, UK
69. Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, UK
70. European Institute for Systems Biology and Medicine (EISBM), Vourles, France
71. Institute of Experimental Medicine and Systems Biology, Faculty of Medicine, RWTH, Aachen University, Aachen, Germany
72. The Roslin Institute, University of Edinburgh EH25 9RG
73. University of Lausanne, Lausanne, Switzerland
74. Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany
75. St. John's University College of Pharmacy and Health Sciences, Queens, NY USA
76. FPS/ELIXIR-es, Hospital Virgen del Rocío, Sevilla, 42013, Spain
77. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
78. Systems Biology Institute, Tokyo Japan
79. Okinawa Institute of Science and Technology Graduate School
80. FAIRDOMHub: <https://fairdomhub.org/projects/190>

Abstract

We hereby describe a large-scale community effort to build an open-access, interoperable, and computable repository of COVID-19 molecular mechanisms - the COVID-19 Disease Map. We discuss the tools, platforms, and guidelines necessary for the distributed development of its contents by a multi-faceted community of biocurators, domain experts, bioinformaticians, and computational biologists. We highlight the role of relevant databases and text mining approaches in enrichment and validation of the curated mechanisms. We describe the contents of the map and their relevance to the molecular pathophysiology of COVID-19 and the analytical and computational modelling approaches that can be applied to the contents of the COVID-19 Disease Map for mechanistic data interpretation and predictions. We conclude by demonstrating concrete applications of our work through several use cases.

1. Introduction

The coronavirus disease 2019 (COVID-19) pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] has already resulted in the infection of over 40 million people worldwide, of whom one million have died¹. The molecular pathophysiology that links SARS-CoV-2 infection to the clinical manifestations and course of COVID-19 is complex and spans multiple biological pathways, cell types and organs [2,3]. To gain the insights into this complex network, the biomedical research community needs to approach it from a systems perspective, collecting the mechanistic knowledge scattered across the scientific literature and bioinformatic databases, and integrating it using formal systems biology standards.

With this goal in mind, we initiated a collaborative effort involving over 230 biocurators, domain experts, modelers and data analysts from 120 institutions in 30 countries to develop the COVID-19 Disease Map, an open-access collection of curated computational diagrams and models of molecular mechanisms implicated in the disease [4].

To this end, we aligned the biocuration efforts of the Disease Maps Community [5,6], Reactome [7], and WikiPathways [8] and developed common guidelines utilising standardised encoding and annotation schemes, based on community-developed systems biology standards [9–11], and persistent identifier repositories [12]. Moreover, we integrated relevant knowledge from public repositories [13–16] and text mining resources, providing a means to update and refine contents of the map. The fruit of these efforts was a series of pathway diagrams describing key events in the COVID-19 infectious cycle and host response.

¹ <https://covid19.who.int/>

We ensured that this comprehensive diagrammatic description of disease mechanisms is machine-readable and computable. This allows us to develop novel bioinformatics workflows, creating executable networks for analysis and prediction. In this way, the map is both human and machine-readable, lowering the communication barrier between biocurators, domain experts, and computational biologists significantly. Computational modelling, data analysis, and their informed interpretation using the contents of the map have the potential to identify molecular signatures of disease predisposition and development, and to suggest drug repositioning for improving current treatments.

COVID-19 Disease Map is a collection of 41 diagrams containing 1836 interactions between 5499 elements, supported by 617 publications and preprints. The summary of diagrams available in the COVID-19 Disease Map can be found online² in Supplementary Material 1. The map is a constantly evolving resource, refined and updated by ongoing efforts of biocuration, sharing and analysis. Here, we report its current status.

In Section 2 we explain the set up of our community effort to construct the interoperable content of the resource, involving biocurators, domain experts and data analysts. In Section 3 we demonstrate that the scope of the biological maps in the resource reflects the state-of-the-art about the molecular biology of COVID-19. Next, we outline analytical workflows that can be used on the contents of the map, including initial, preliminary outcomes of two such workflows, discussed in detail as use cases in Section 4. We conclude in Section 5 with an outlook to further development of the COVID-19 map and the utility of the entire resource in future efforts towards building and applying disease-relevant computational repositories.

² https://covid.pages.uni.lu/map_contents

2. Building and sharing the interoperable content

The COVID-19 Disease Map project involves three main groups: (i) biocurators, (ii) domain experts, and (iii) analysts and modellers:

- i. Biocurators develop a collection of systems biology diagrams focused on the molecular mechanisms of SARS-CoV-2.
- ii. Domain experts refine the contents of the diagrams, supported by interactive visualisation and annotations.
- iii. Analysts and modellers develop computational workflows to generate hypotheses and predictions about the mechanisms encoded in the diagrams.

All three groups have an important role in the process of building the map, by providing content, refining it, and defining the downstream computational use of the map. Figure 1 illustrates the ecosystem of the COVID-19 Disease Map Community, highlighting the roles of different participants, available format conversions, interoperable tools, and downstream uses. The information about the community members and their contributions are disseminated via the FAIRDOMHub [17], so that content distributed across different collections can be uniformly referenced.

2.1 Creating and accessing the diagrams

The biocurators of the COVID-19 Disease Map diagrams follow the guidelines developed by the Community, and specific workflows of WikiPathways [8] and Reactome [7]. The biocurators build literature-based systems biology diagrams, representing the molecular processes implicated in the COVID-19 pathophysiology, their complex regulation and the phenotypic outcomes. These diagrams are main building blocks of the map, and are composed of biochemical reactions and interactions (further called altogether interactions) taking place between different types of molecular entities in various cellular compartments. As there are multiple teams working on related topics, biocurators can provide an expert review across pathways and across platforms. This is possible, as all platforms offer intuitive visualisation, interpretation, and analysis of pathway knowledge to support basic and clinical research, genome analysis, modelling, systems biology, and education. Table 1 lists information about the created content. For more details see Supplementary Material 1.




Figure 1: The ecosystem of the COVID-19 Disease Map Community. The main groups of COVID-19 Disease Map Community are biocurators, domain experts, analysts, and modellers; communicating to refine, interpret and apply COVID-19 Disease Map diagrams. These diagrams are created and maintained by biocurators, following pathway database workflows or standalone diagram editors, and reviewed by domain experts. The content is shared via pathway databases or a GitLab repository; all can be enriched by integrated resources of text mining and interaction databases. The COVID-19 Disease Map diagrams, available in layout-aware systems biology formats and integrated with external repositories, are available in several formats allowing a range of computational analyses, including network analysis and Boolean, kinetic or multiscale simulations.

Both interactions and interacting entities are annotated following a uniform, persistent identification scheme, using either MIRIAM or Identifiers.org [18], and the guidelines for annotations of computational models [19]. Viral protein interactions are explicitly annotated with their taxonomy identifiers to highlight findings from strains other than SARS-CoV-2. Moreover, tools like ModelPolisher [20], SBMLsqueezer [21] or MEMOTE³ help to automatically complement the annotations in the SBML format and validate the model (see also Supplementary Material 2).

³ <https://memote.io>

Table 1. COVID-19 Disease Map contents. The table summarises biocuration resources and content of the map across three main parts of the repository. All diagrams are listed in Supplementary Material 1.

	Source		
	Individual diagrams	Reactome	WikiPathways
Diagram contents	21 diagrams 1334 interactions 4272 molecular entities 397 publications	1 diagram 101 interactions 489 molecular entities 227 publications	19 diagrams 401 interactions 738 molecular entities 61 publications
Access	Gitlab git-r3lab.uni.lu/covid/models	SARS-CoV infections collection reactome.org/PathwayBrowser/#/R-HSA-9679506	COVID pathways collection covid.wikipathways.org
Exploration	The MINERVA Platform [22] covid19map.elixir-luxembourg.org Guide: covid.pages.uni.lu/minerva-guide	Native web interface Guide: Link to instructions	Native web interface Guide: Link to instructions
Biocuration guidelines	Community ⁴	Community ⁵ Platform-specific ⁵	Community ⁵ Platform-specific ⁶
Diagram Editors	CellDesigner ⁷ Newt ⁸ SBGN-ED [23] yEd+ySBGN ⁹	Reactome pathway editor ⁶	PathVisio [24]
Formats	CellDesigner SBML [25] SBGNML [26,27]	Internal, SBML and SBGNML compliant	GPML [24]

2.2 Enrichment using knowledge from databases and text mining

The knowledge on COVID-19 mechanisms is rapidly evolving, as demonstrated by the rapid growth of the COVID-19 Open Research Dataset (CORD-19) dataset, a source scientific

⁴ https://docs.google.com/document/d/1DFfjZe2xjXrKMHorp_-7hlqWoNVSmx6sIzAaRzXgtQs

⁵ <https://reactome.org/community/training>

⁶ https://www.wikipathways.org/index.php/Help:Editing_Pathways

⁷ <http://celldesigner.org>

⁸ <https://newteditor.org>

⁹ <https://github.com/sbgn/ySBGN>

manuscript text and metadata on COVID-19 and related coronavirus research [28]. COVID-19 currently contains over 130,000 articles and preprints, over four times more than when it was introduced¹⁰. In such a quickly evolving environment, biocuration efforts need to be supported by other repositories of structured knowledge about molecular mechanisms relevant for COVID-19, like molecular interaction databases, or text mining resources. Contents of such repositories may suggest improvements in the existing COVID-19 Disease Map diagrams, or establish a starting point for developing new pathways (see Section “Biocuration of database and text mining content”).

Interaction and pathway databases

Interaction and pathway databases contain structured and annotated information on protein interactions or causal relationships. While interaction databases focus on pairs of molecules, offering broad coverage of literature-reported findings. Pathway databases provide detailed description of biochemical processes and their regulations of related interactions, supported by diagrams. Both types of resources can be a valuable input for COVID-19 Disease Map biocurators, given the comparability of identifiers used for molecular annotations, and the reference to publications used for defining an interaction or building a pathway. Table 2 summarises open-access resources supporting the biocuration of the map. See Supplementary Materials [tools] for their detailed description.

Table 2. Resources supporting biocuration of the COVID-19 Disease Map. They include (i) collections of COVID-19 interactions by the IMEx Consortium [14] and the SIGNOR 2.0 [15], (ii) non-COVID mechanistic interaction database OmniPath [13] and (iii) the Elsevier Pathway Collection, a manually reconstructed open-access dataset of annotated pathway diagrams for COVID-19¹¹.

Resource	Type	Manually curated	Directed	Layout	COVID-19 specific
IMEx Consortium database [29]	Interaction	Yes	No	No	Yes ¹² [14]
SIGNOR 2.0 database [15]	Interaction	Yes	Yes	Yes	Yes ¹³
OmniPath database [13]	Interaction	No	Yes	No	No
Elsevier Pathway Collection ¹⁴	Pathway	Yes	Yes	Yes	Yes ⁹

¹⁰ <https://www.semanticscholar.org/cord19/download> (accessed on 20.10.2020)

¹¹ <https://data.mendeley.com/datasets/h9vs5s8fz2/draft?a=f40961bb-9798-4fd1-8025-e2a3ba47b02e>

¹² <https://www.imexconsortium.org>

¹³ <https://signor.uniroma2.it/covid/>

¹⁴ <https://pathwaystudio.com>

Text mining resources

Text-mining approaches can help to sieve through such rapidly expanding literature with natural language processing (NLP) algorithms based on semantic modelling, ontologies, and linguistic analysis to automatically extract and annotate relevant sentences, biomolecules, and their interactions. This scope was recently extended to pathway figure mining: decoding pathway figures into their computable representations [30]. Altogether, these automated workflows lead to the construction of knowledge graphs: semantic networks incorporating ontology concepts, unique biomolecule references, and their interactions extracted from abstracts or full-text documents [31].

The COVID-19 Disease Map Project integrates open-access text mining resources, INDRA [32], BioKB¹⁵, AILANI COVID-19¹⁶, and PathwayStudio¹⁰. All platforms offer keyword-based search allowing interactive exploration. Additionally, the map benefits from an extensive protein-protein interaction network (PPI)¹⁷ generated with a custom text-mining pipeline using OpenNLP¹⁸ and GNormPlus [33]. This pipeline was applied to the COVID-19 dataset and the collection of MEDLINE abstracts associated with the genes in the SARS-CoV-2 PPI network [34] using the Entrez Gene Reference-Into-Function (GeneRIF). For detailed descriptions of the resources, see Supplementary Material 3.

Biocuration using database and text mining content

Molecular interactions from databases and knowledge graphs from text mining resources discussed above (from now on called altogether ‘knowledge graphs’) have a broad coverage at the cost of depth of mechanistic representation. This content can be used by the biocurators in the process of building and updating the systems biology focused diagrams. Biocurators can use this content in three main ways: by visual exploration, by programmatic comparison, and by direct incorporation of the content.

First, the biocurators can visually explore the contents of the knowledge graphs using available search interfaces to locate new knowledge and encode it in the diagrams. Moreover, solutions like COVIDminer project¹⁹, PathwayStudio and AILANI offer a visual representation of a group of interactions for a better understanding of their biological context, allowing search by interactions, rather than just isolated keywords. Finally, INDRA

¹⁵ <https://biokb.lcsb.uni.lu>

¹⁶ https://ailani.ai/cgi/login_bioxm_portal.cgi

¹⁷ <https://git-r3lab.uni.lu/covid/models/-/tree/master/Resources/Text%20mining>

¹⁸ <https://opennlp.apache.org>

¹⁹ <https://rupertoverall.net/covidminer>

and AILANI offer assistant bots that respond to natural language queries and return meaningful answers extracted from knowledge graphs.

Second, programmatic access and reproducible exploration of the knowledge graphs is possible via data endpoints: SPARQL for BioKB and Application Programming Interfaces for INDRA, AILANI, and Pathway Studio. Users can programmatically submit keyword queries and retrieve functions, interactions, pathways, or drugs associated with submitted gene lists. This way, otherwise time-consuming tasks like an assessment of completeness of a given diagram, or search for new literature evidence, can be automated to a large extent.

Finally, biocurators can directly incorporate the content of knowledge graphs into SBML format using BioKC [35]. Additionally, the contents of the Elsevier COVID-19 Pathway Collection can be translated to SBGNML²⁰ preserving the layout of the diagrams. The SBGNML content can then be converted into other diagram formats used by biocurators (see Section 2.3 below).

2.3 Interoperability of the diagrams and annotations

The biocuration of the COVID-19 Disease Map is distributed across multiple teams, using varying tools and associated systems biology representations. This requires a common approach to annotations of evidence, biochemical reactions, molecular entities and their interactions. Moreover, the interoperability of layout-aware formats is needed for comparison and integration of the diagrams in the map.

Layout-aware formats for molecular mechanisms

The COVID-19 Disease Map diagrams are encoded in one of three layout-aware formats for standardised representation of molecular interactions: SBML²¹ [36–38], SBGNML [27], and GPML [24]. These XML-based formats focus to a varying degree on user-friendly graphical representation, standardised visualisation, and support of computational workflows. For the detailed description of the formats, see Supplementary Material 1.

Each of these three languages has a different focus: SBML emphasizes standardised representation of the data model underlying molecular interactions, SBGNML provides standardised graphical representation of molecular processes, while GPML allows for a partially standardised representation of uncertain biological knowledge. Nevertheless, all three formats are centered around molecular interactions, provide a constrained vocabulary to encode element and interaction types, encode layout of their diagrams and support stable

²⁰ <https://github.com/golovatenkop/rnef2sbgn>

²¹ here, SBML stands for two formats: CellDesigner SBML and SBML with *layout* and *render* packages

identifiers for diagram components. These shared properties, supported by a common ontology²² [39], allow cross-format mapping and enable translation of key properties between the formats. Therefore, when developing the contents of the map, biocurators use the tools they are familiar with, facilitating this distributed task.

Format interoperability

The COVID-19 Disease Map Community ecosystem of tools and resources (see Figure 1) ensures interoperability between the three layout-aware formats for molecular mechanisms: SBML, SBGNML, and GPML. Essential elements of this setup are tools capable of providing cross-format translation functionality [40,41] and supporting harmonised visualisation processing. Another essential translation interface is a representation of Reactome pathways in WikiPathways GPML [42] and SBML. The SBML export of Reactome content has been optimised in the context of this project and facilitates integration with the other COVID-19 Disease Map software components.

The contents of the COVID-19 Disease Map diagrams can be directly transformed into inputs of computational pipelines and data repositories. Besides the direct use of SBML format in kinetic simulations, CellDesigner SBML files can be transformed into SBML qual [43] using CaSQ [44], enabling Boolean modelling-based simulations (see also Supplementary Material 3). In parallel, CaSQ converts the diagrams to the SIF format²³, supporting pathway modelling workflows using simplified interaction networks. Notably, the GitLab repository features an automated translation of stable versions of diagrams into SBML qual. Finally, translation of the diagrams into XGMML format (the eXtensible Graph Markup and Modelling Language) using Cytoscape [45] or GINSim [46] allows for network analysis and interoperability with molecular interaction repositories [47].

3. Structure and scope of the map

Thanks to the community effort discussed above supported by a rich bioinformatics framework, we constructed the COVID-19 Disease Map, focussing on the mechanisms known from other coronaviruses [48] and suggested by early experimental investigations [PMID:32511329]. Then, we applied the analytical and modelling workflows to the contributed diagrams and associated interaction databases to propose initial map-based insights into COVID-19 molecular mechanisms.

The COVID-19 Disease Map is an evolving repository of pathways affected by SARS-CoV-2. Figure 2. It is currently centred on molecular processes involved in SARS-CoV-2 entry,

²² <http://www.ebi.ac.uk/sbo/main/>

²³ <http://www.cbmc.it/fastcent/doc/SifFormat.htm>

replication, and host-pathogen interactions. As mechanisms of host susceptibility, immune response, cell and organ specificity emerge, these will be incorporated into the next versions of the map.




Figure 2: The structure and content of the COVID-19 Disease Map. The areas of focus of the COVID-19 Map biocuration.

The COVID-19 Map represents the mechanisms in a “host cell”. This follows literature reports on cell specificity of SARS-CoV-2 [3,49–53]. Some pathways included in the COVID-19 Map may be shared among different cell types, as for example the IFN-1 pathway found in cells such as dendritic, epithelial, and alveolar macrophages [54–58]. While at this stage, we do not address cell specificity explicitly in our diagrams, extensive annotations may allow identification of pathways relevant to the cell type of interest.

The SARS-CoV-2 infection process and COVID-19 progression follow a sequence of steps (Figure 3), starting from viral attachment and entry, which involve various dynamic processes on different time scales that are not captured in static representations of pathways. Correlation of symptoms and potential drugs suggested to date helps downstream data exploration and drug target interpretation in the context of therapeutic interventions.




Figure 3: Overview of the map in the context of COVID-19 progression. Pathways and cell types involved in the sequential stages of COVID-19, including some of the most common clinical manifestations and medical management from the moment of infection to the disease resolution, are shown. The distribution of the elements is for illustrative reference and does not necessarily indicate either a unique/static interplay of these elements or an unvarying progression. For the literature on clinical manifestations see [59–65].

Supplementary Material 1 summarises the contents of the COVID-19 Disease Map diagrams, their central platform of reference. The online version of the table is continuously updated to reflect the evolving content of the COVID-19 Disease Map²⁴.

3.1 Virus replication cycle and subversion of host defence

Virus attachment and entry

Transmission of SARS-CoV-2 primarily occurs through contact with respiratory drops, airborne transmission, and through contact with contaminated surfaces [66–68]. Upon contact with the respiratory epithelium, the virus infects cells mostly by binding the spike surface glycoprotein (S) to angiotensin-converting enzyme 2 (ACE2) with the help of serine protease TMPRSS2 [69–72]. Importantly, recent results suggest viral entry using other receptors of lungs and the immune system [73,74]. Once attached, SARS-CoV-2 can enter cells either by direct fusion of the virion and cell membranes in the presence of proteases

²⁴ https://covid.pages.uni.lu/map_contents

TMPRSS2 and furin or by endocytosis in their absence. Regardless of the entry mechanism, the S protein has to be activated to initiate the plasma or endosome membrane fusion process. While in the cell membrane, S protein is activated by TMPRSS2 and furin, in the endosome S protein is activated by cathepsin B (CTSB) and cathepsin L (CTSL) [71,75]. Activated S promotes the cell- or endosome-membrane fusion [76] with the virion membrane, and then the nucleocapsid is injected into the cytoplasm. These mechanisms are represented in the corresponding diagrams of the map²⁵.

Replication and release

Within the host cell, SARS-CoV-2 hijacks the rough endoplasmic reticulum (RER)-linked host translational machinery. It then synthesises viral proteins replicase polyprotein 1a (pp1a) and replicase polyprotein 1ab (pp1ab) directly from the virus (+)genomic RNA (gRNA) [48,77]. Through a complex cascade of proteolytic cleavages, pp1a and pp1ab give rise to 16 non-structural proteins (Nsp) [78–80]. Most of these Nsp collectively form the replication transcription complex (RTC) that is anchored to the membrane of the double-membrane vesicle [78,81], a coronavirus replication organelle induced by Nsp 3, 4, and 6 [82]. RTC is thought to play two main roles: 1) triggering the synthesis of both (+)gRNA and (+)subgenomic messenger RNAs (sgmRNAs) via negative-stranded templates [83–85]; and 2) protecting intermediate double-stranded RNAs from the cell innate immunity sensors [86]. The (+)sgmRNAs are translated by the RER-attached translation machinery into structural (E, M, N and S) and accessory proteins (Orf3a, Orf6, Orf7a/b, Orf8, Orf9b, Orf10 and Orf14). The structural proteins and the newly generated (+)gRNAs are assembled into new virions in the endoplasmic reticulum-Golgi intermediate compartment. These are released to the extracellular space via smooth-walled vesicles [48,77].

Endoplasmic reticulum stress and unfolded protein response

As discussed above, the virus hijacks the ER to replicate. Production of large amounts of viral proteins exceeds the protein folding capacity of the ER, creating an overload of unfolded proteins. As a result, the unfolded protein response (UPR) pathways are triggered to assure the ER homeostasis, using three main signalling routes of UPR via PERK, IRE1, and ATF6 [87]. Their role is to mitigate the misfolded protein load and reduce oxidative stress. The resulting protein degradation is coordinated with a decrease in protein synthesis via eIF2alpha phosphorylation and induction of protein folding genes via the transcription factor XBP1 [88]. When the ER is unable to restore its function, it can trigger cell apoptosis [89,90].

²⁵ <https://covid19map.elixir-luxembourg.org/minerva/?search%3Dvirus%2520replication%2520cycle>

The results are ER stress and activation of the UPR. The expression of some human coronavirus (HCoV) proteins during infection, in particular the S glycoprotein, may induce activation of the ER stress in the host cells [91]. Based on SARS-CoV results, this may lead to activation of the PERK [92], IRE1 and in an indirect manner, of the ATF6 pathways [93].

Autophagy and protein degradation

Processes of degrading malfunctioning proteins and damaged organelles, including the ubiquitin-proteasome system (UPS) and autophagy [94] are essential to maintain energy homeostasis and prevent cellular stress [95,96]. Autophagy is also involved in cell defence, including direct destruction of the viruses via virophagy, presentation of viral antigens, and inhibition of excessive inflammatory reactions [97,98].

SARS-CoV-2 directly affects the process of UPS-based protein degradation, as indicated by the host-virus interactome dataset published recently [34]. This mechanism may be a defence against viral protein degradation [99]. The map describes in detail the nature of this interaction, namely the impact of Orf10 virus protein on the Cul2 ubiquitin ligase complex and its potential substrates.

Interactions between SARS-CoV-2 and host autophagy pathways are inferred based on results from other CoVs. A finding that CoVs use double-membrane vesicles and LC3-I for replication [100] may suggest that the virus induces autophagy, possibly in ATG5-dependent manner [101], although some evidence points to the contrary [102]. Also, the CoV Nsp6 restricts autophagosome expansion, compromising the degradation of viral components [103]. Recently revealed mutations in Nsp6 [104] indicate its importance, although the exact effect of the mutations remains unknown. Based on the connection between autophagy and the endocytic pathway of the virus replication cycle [105], autophagy modulation was suggested as a potential therapy strategy, either pharmacologically [96,105–107], or via fasting [108].

Apoptosis

Apoptosis, a synonym for programmed cell death, is triggered by virus-host interaction upon infection, as the early death of the virus-infected cells may prevent viral replication. Many viruses block or delay cell death by expressing anti-apoptotic proteins to maximize the production of viral progeny [109]. In turn, apoptosis induction at the end of the viral replication cycle might assist in viral dissemination while reducing an inflammatory response. For instance, SARS-CoV-2 [110] and MERS [111] are able to invoke apoptosis in lymphocytes, compromising the immune system.

Apoptosis follows two major pathways [112], called extrinsic and intrinsic. Extrinsic signals are transmitted by death ligands and their receptors (e.g., FasL and TNF-alpha). Activated death receptors recruit adaptors like FADD and TRADD, and initiator procaspases like

caspase-8, leading to cell death with the help of effector caspases-3 and 7 [113,114]. In turn, the intrinsic pathway involves mitochondria-related members of the Bcl-2 protein family. Cellular stress causes Bcl-2 proteins-mediated release of cytochrome c from the mitochondria into the cytoplasm. Cytochrome c then forms a complex with Apaf1 and recruits initiator procaspase-9 to form the apoptosome, leading to the proteolytic activation of caspase-9. Activated caspase-9 can now initiate the caspase cascade by activating effector caspases 3 and 7 [114]. The intrinsic pathway is modulated by SARS-CoV molecules [115,116]. As intrinsic apoptosis involves mitochondria, its activity may also be exacerbated by SARS-CoV-2 disruptions of the electron transport chain, mitochondrial translation, and transmembrane transport [34]. The resulting mitochondrial dysfunction may lead to increased release of reactive oxygen species and pro-apoptotic factors.

Another vital crosstalk is that of the intrinsic pathway with the PI3K-Akt pro-survival pathway. Activated Akt can phosphorylate and inactivate various pro-apoptotic proteins, including Bad and caspase-9 [117]. SARS-CoV uses PI3K-Akt signalling cascade to enhance infection [118]. Moreover, SARS-CoV could affect apoptosis in a cell-type-specific manner [119,120].

SARS-CoV structural proteins S, E, M, N, and accessory proteins 3a, 3b, 6, 7a, 8a, and 9b have been shown to act as crucial effectors of apoptosis in vitro. Structural proteins seem to affect mainly the intrinsic apoptotic pathway, with p38 MAPK and PI3K/Akt pathways regulating cell death. Accessory proteins can induce apoptosis via different cascades and in a cell-specific manner [114]. SARS-CoV E and 7a protein were shown to activate the intrinsic pathway by blocking anti-apoptotic Bcl-XL localized to the ER [121]. SARS-CoV M protein and the ion channel activity of E and 3a were shown to interfere with pro-survival signalling cascades [114,122].

3.2 Integrative stress response: endothelial damage, coagulation, and inflammation

The viral replication and the consequent immune and inflammatory responses cause damage to the epithelium and pulmonary capillary vascular endothelium and activate the main intracellular defence mechanisms, as well as the humoral and cellular immune responses. Resulting cellular stress and tissue damage [123,124] impair respiratory capacity and lead to acute respiratory distress syndrome (ARDS) [61,125,126]. Hyperinflammation is a known complication, causing widespread damage, organ failure, and death, followed by a not yet completely understood rapid increase of cytokine levels (cytokine storm) [127–129], and acute ARDS [130]. Other reported complications, such as coagulation disturbances and thrombosis are associated with severe cases, but the specific mechanisms are still

unknown [64,131–133], although some reports suggest that COVID-19 coagulopathy has a distinct profile [134].

The SARS-CoV-2 infection disrupts the coagulation cascade and is frequently associated with hyperinflammation, renin-angiotensin system (RAS) imbalance and intravascular coagulopathy [132,135–137]. Hyperinflammation leads in turn to detrimental hypercoagulability and immunothrombosis, leading to microvascular thrombosis with further organ damage [138]. Importantly, RAS is influenced by risk factors of developing severe forms of COVID-19 [139–141].

ACE2, used by SARS-CoV-2 for host cell entry, is a regulator of RAS and is widely expressed in the affected organs [142]. The main function of ACE2 is the conversion of AngII to angiotensin 1-7 (Ang1-7), and these two angiotensins trigger the counter-regulatory arms of RAS [143]. The signalling via AngII and its receptor AGTR1, elevated in the infected [142,144], induces the coagulation cascade leading to microvascular thrombosis [145], while Ang1-7 and its receptor MAS1 attenuate these effects [143].

3.4 Innate immune response

PAMP signalling

The innate immune system detects specific pathogen-associated molecular patterns (PAMPs), through Pattern Recognition Receptors (PRRs). Detection of SARS-CoV-2 is mediated through receptors that recognise double-stranded and single-stranded RNA in the endosome during endocytosis of the virus particle, or in the cytoplasm during the viral replication. These receptors mediate the activation of transcription factors such as AP1, NFkappaB, IRF3, and IRF7, responsible for the transcription of antiviral proteins, in particular, interferon-alpha and beta [146,147].

SARS-CoV-2 reduces the production of type I interferons to evade the immune response [49]. The detailed mechanism is not clear yet; however, SARS-CoV M protein inhibits the IRF3 activation [148] and suppresses *NFkappaB* and *COX2* transcription. At the same time, SARS-CoV N protein activates NFkappaB [149], so the overall impact is unclear. These pathways are also negatively regulated by SARS-CoV nsp3 papain-like protease domain (PLPro) [150].

The map contains the initial recognition process of the viral particle by the innate immune system and the viral mechanisms to evade the immune response. It provides the connection between virus entry (detecting the viral endosomal patterns), its replication cycle (detection cytoplasmic viral patterns), and the effector pathways of pro-inflammatory cytokines, especially of the interferon type I class. The latter seems to play a crucial but complex role in COVID-19 pathology: both negative [151,152] and positive effects [3,153] of interferons on virus replication have been reported.

Interferon type I signalling

Interferons (IFNs) are central players in the antiviral immune response of the host cell [55], specifically affected by SARS-CoV-2 [154–157]. Type I IFNs are induced upon viral recognition of PAMPs by various host PRRs [48] as discussed earlier. The IFN-I pathway diagram represents the activation of TLR7 and IFNAR and the subsequent recruiting of adaptor proteins and the downstream signalling cascades regulating key transcription factors including IRF3/7, NF-kappaB, AP-1, and ISRE [48,158]. Further, the map shows IRF3-mediated induction of IFN-I, affected by the SARS-CoV-2 proteins. SARS-CoV Nsp3 and Orf6 interfere with IRF3 signalling [159,160] and SARS-CoV M, N, Nsp1 and Nsp3 act as interferon antagonists [48,150,158,161,162]. Moreover, coronaviruses ORF3a, ORF6 and nsp1 proteins can repress interferon expression and stimulate the degradation of IFNAR1 and STAT1 during the Unfolded Protein Response (UPR) [163,164].

Another mechanism of viral RNA recognition is RIG-like receptor signalling [58], leading to STING activation [165], and via the recruitment of TRAF3, TBK1 and IKKepsilon to phosphorylation of IRF3 [56]. This in turn induces the transcription of IFNs alpha, beta and lambda [166]. SARS-CoV viral papain-like-proteases, contained within the nsp3 and nsp 16 proteins, inhibit STING and the downstream IFN secretion [167]. In line with this hypothesis, SARS-CoV-2 infection results in a unique inflammatory response defined by low levels of IFN-I and high expression of cytokines [58,168]. The IFNlambda diagram describes the IFNL receptor signaling cascade [169], including JAK-STAT signaling and the induction of Interferon Stimulated Genes, which encode antiviral proteins [170]. The interactions of SARS-CoV-2 proteins with the IFNL pathway are based on the literature [171] or SARS-CoV homology [58].

Altered host metabolism

Metabolic pathways govern the immune microenvironment by modulating the availability of nutrients and critical metabolites [172]. Infectious entities reprogram host metabolism to create favourable conditions for their reproduction [173]. SARS-CoV-2 proteins interact with a variety of immunometabolic pathways, several of which are described below.

Heme catabolism is a well-known anti-inflammatory system in the context of infectious and autoimmune diseases [174,175]. The main effector of this pathway, heme oxygenase-1 (HMOX1) was found to interact with SARS-CoV-2 Orf3a, although the nature of this interaction remains ambiguous [34,176]. HMOX1 cleaves heme into carbon monoxide, biliverdin (then reduced to bilirubin), and ferrous iron [PMID:31396090]. Biliverdin, bilirubin, and carbon monoxide possess cytoprotective properties, and have shown promise as immunomodulatory therapeutics [177,178]. Importantly, activation of HMOX1 also inhibits the NLRP3 inflammasome [178–180], which is a pro-inflammatory and prothrombotic multiprotein system [181] highly active in COVID-19 [182–184]. It mediates

production of the pro-inflammatory cytokines IL-1B and IL-18 via caspase-1 [181]. The SARS-CoV Orf3a, E, and Orf8a incite the NLRP3 inflammasome [185–188]. Still, the potential of the HMOX1 pathway to fight COVID-19 inflammation remains to be tested [176,189,190] despite promising results in other models of inflammation [176,178,191–193].

The tryptophan-kynurenine pathway is closely related to heme metabolism. The rate-limiting step of this pathway is catalysed by the indoleamine 2,3 dioxygenase enzymes (IDO1 and IDO2) in dendritic cells, macrophages, and epithelial cells in response to inflammatory cytokines like IFN-gamma, IFN-1, TGF-beta, TNF-alpha, and IL-6 [194–196]. Crosstalk with the HMOX1 pathway also increases the expression of IDO1 and HMOX1 in a feed-forward manner. Metabolomics analyses from severe COVID-19 patients revealed enrichment of kynurenines and depletion of tryptophan, indicating robust activation of IDO enzymes [197,198]. Depletion of tryptophan [173,199,200] and kynurenines and their derivatives affect the proliferation and immune response of a range of T cells [176,201–205]. However, despite high levels of kynurenines in COVID-19, CD8+ T-cells and Th17 cells are enriched in lung tissue, and T-regulatory cells are diminished [206]. This raises the question of whether and how the immune response elicited in COVID-19 evades suppression by the kynurenine pathway.

The SARS-CoV-2 protein Nsp14 interacts with three human proteins: GLA, SIRT5, and IMPDH2 [34]. The galactose metabolism pathway, including the GLA enzyme [207], is interconnected with amino sugar and nucleotide sugar metabolism. SIRT5 is a NAD-dependent desuccinylase and demalonylase regulating serine catabolism, oxidative metabolism and apoptosis initiation [208–210]. Moreover, nicotinamide metabolism regulated by SIRT5 occurs downstream of the tryptophan metabolism, linking it to the pathways discussed above. Finally, IMPDH2 is the rate-limiting enzyme in the *de novo* synthesis of GTP, allowing regulation of purine metabolism and downstream potential antiviral targets [211,212].

The pyrimidine synthesis pathway, tightly linked to purine metabolism, affects viral DNA and RNA synthesis. Pyrimidine deprivation is a host targeted antiviral defence mechanism, which blocks viral replication in infected cells and can be regulated pharmacologically [213–215]. It appears that components of the DNA damage response connect the inhibition of pyrimidine biosynthesis to the interferon signalling pathway, probably via STING-induced TBK1 activation that amplifies interferon response to viral infection, discussed above. Inhibition of *de novo* pyrimidine synthesis may have beneficial effects on the recovery from COVID-19 [215]; however, this may happen only in a small group of patients.

3.5 Biocuration roadmap

COVID-19 pathways featured in the previous section cover mechanisms reported so far. Still, certain aspects of the disease were not represented in detail because of their complexity, namely cell-type-specific immune response, and susceptibility features. Their mechanistic description is of great importance, as suggested by clinical reports on the involvement of these pathways in the molecular pathophysiology of the disease. The mechanisms outlined below will be the next targets in our curation roadmap.

Cell type-specific immune response

COVID-19 causes serious disbalance in multiple populations of immune cells. Some studies report that COVID-19 patients have a significant decrease of peripheral CD4+ and CD8+ cytotoxic T lymphocytes (CTLs), B cells, NK cells, as well as higher levels of a broad range of cytokines and chemokines [128,216–219]. The disease causes functional exhaustion of CD8+ CTLs and NK cells, induced by SARS-CoV-2 S protein and by excessive pro-inflammatory cytokine response [217,220]. Moreover, the ratio of naïve-to-memory helper T-cells, as well as the decrease of T regulatory cells, correlate with COVID-19 severity [206]. Conversely, high levels of Th17 and cytotoxic CD8+ T-cells have been found in the lung tissue [221]. Pulmonary recruitment of lymphocytes into the airways may explain the lymphopenia and the increased neutrophil-lymphocyte ratio in peripheral blood found in COVID-19 patients [216,222,223]. In this regard, an abnormal increase of the Th17:Treg cell ratio may promote the release of pro-inflammatory cytokines and chemokines, increasing disease severity [224].

Susceptibility features of the host

SARS-CoV-2 infection is associated with increased morbidity and mortality in individuals with underlying chronic diseases or a compromised immune system [225–228]. Groups of increased risk are men, pregnant and postpartum women, and individuals with high occupational viral exposure [229–231]. Other susceptibility factors include the ABO blood groups [232–240] and respiratory conditions [241–246].

Importantly, age is one of the key aspects contributing to the severity of the disease. The elderly are at high risk of developing severe or critical disease [227,247]. Age-related elevated levels of pro-inflammatory cytokines (inflammation) [247–250], immunosenescence and cellular stress of ageing cells [125,227,247,251,252] may contribute to the risk. In contrast, children are generally less likely to develop severe disease [253,254], with the exception of infants [125,255–257]. However, some previously healthy children and adolescents can develop a multisystem inflammatory syndrome following SARS-CoV-2 infection [258–262].

Several genetic factors have been proposed and identified to influence susceptibility and severity, including the ACE2 gene, HLA locus, errors influencing type I IFN production, TLR pathways, myeloid compartments, as well as cytokine polymorphisms [156,235,263–269].

We aim to connect the susceptibility features to specific molecular mechanisms and better understand the contributing factors. This can lead to a series of testable hypotheses, including the role of vitamin D counteracting pro-inflammatory cytokine secretion [270–272] in an age-dependent manner [247,273], and modifying the severity of the disease. Another example of a testable hypothesis may be that the immune phenotype associated with asthma inhibits pro-inflammatory cytokine production and modifies gene expression in the airway epithelium, protecting against severe COVID-19 [245,246,274].

4. Bioinformatics analysis and computational modelling roadmap for hypothesis generation

In order to understand complex and often indirect dependencies between different pathways and molecules, we need to combine computational and data-driven analyses. Standardised representation and programmatic access to the contents of the COVID-19 Disease Map enable the development of reproducible analytical and modelling workflows. Here, we discuss the range of possible approaches and demonstrate preliminary results, focusing on interoperability, reproducibility, and applicability of the methods and tools.

Our goal is to work on the computational challenges as a community, involving the biocurators and domain experts in the analysis of the COVID-19 Disease Map and rely on their feedback to evaluate the outcomes. In this way, we aim to identify approaches to tackle the complexity and the size of the map, proposing a state-of-the-art framework for robust analysis, reliable models, and useful predictions.

4.1 Data integration and network analysis

Visualisation of omics data can help contextualise the map with experimental data creating data-specific blueprints. These blueprints could be used to highlight parts of the map that are active in one condition versus another (treatment versus control, patient versus healthy, normal versus infected cell, etc.). Combining information contained in multiple omics platforms can make patient stratification more powerful, by reducing the number of samples needed or by augmenting the precision of the patient groups [275,276]. Approaches that integrate multiple data types without the accompanying mechanistic diagrams [277–279] produce patient groupings that are difficult to interpret. In turn, classical pathway analyses often produce long lists mixing generic and cell-specific pathways, making it challenging to

pinpoint relevant information. Using disease maps to interpret omics-based clusters addresses the issues related to contextualised visual data analytics.

Footprint based analysis

Footprints are signatures of a molecular regulator determined by the expression levels of its targets [280]. For example, a footprint can contain targets of a transcription factor (TF) or peptides phosphorylated by a kinase. Combining multiple omics readouts and multiple measurements can increase the robustness of such signatures. Nevertheless, an essential component is the mechanistic description of the targets of a given regulator, allowing computation of its footprint. With available SARS-CoV-2 related omics and interaction datasets [281], it is possible to infer which TFs and signalling pathways are affected upon infection [282]. Combining the COVID-19 Disease map regulatory interactions with curated collections of TF-target interactions like DoRothEA [283] will provide a contextualised evaluation of the effect of SARS-CoV-2 infection at the TF level.

Viral–host interactome

The virus–host interactome is a network of virus-human protein-protein interactions (PPIs) that can help understanding the mechanisms of disease [34,284–286]. It can be expanded by merging virus-host PPI data with human PPI and protein data [287] to discover clusters of interactions indicating human mechanisms and pathways affected by the virus [288]. These clusters first of all can be interpreted at the mechanistic level by visual exploration of COVID-19 Disease Map diagrams. In addition, these clusters can potentially reveal additional pathways to add to the COVID-19 Disease Map (e.g., E protein interactions or TGFβ diagrams) or suggest new interactions to introduce into the existing diagrams.

4.2 Mechanistic and dynamic computational modelling

Computational modelling is a powerful approach that enables *in silico* experiments, produces testable hypotheses, helps elucidate regulation and, finally, can suggest via predictions novel therapeutic targets and candidates for drug repurposing.

Mechanistic pathway modelling

Mechanistic models of pathways allow bridging variations at the scale of molecular activity to variations at the level of cell behaviour. This can be achieved by coupling the molecular interactions of a given pathway with its endpoint and by contextualising the molecular activity using omics datasets. HiPathia is such a method, processing transcriptomic or genomic data to estimate the functional profiles of a pathway conditioned by the data studied and linkable to phenotypes such as disease symptoms or other endpoints of interest [289,290]. Moreover, such mechanistic modelling can be used to predict the effect of

interventions as, for example, the effect of targeted drugs [291]. HiPathia integrates directly with the diagrams of the COVID-19 Map using the SIF format provided by CaSQ (see Section 2.3), as well as with the associated interaction databases (see Section 2.2).

The drawback of approaches like HiPathia is their computational complexity, limiting the size of the diagrams they can process. An approach to large-scale mechanistic pathway modelling is to transform them into causal networks. CARNIVAL [292] combines the causal representation of networks [13] with transcriptomics, phosphoproteomics, or metabolomics data [280] to contextualise cellular networks and extract mechanistic hypotheses. The algorithm identifies a set of coherent causal links connecting upstream drivers such as stimulations or mutations to downstream changes in transcription factor activities.

Discrete computational modelling

Analysis of the dynamics of molecular networks is necessary to understand their dynamics and deepen our understanding of crucial regulators behind disease-related pathophysiology. Discrete modelling framework provides this possibility. COVID-19 Disease Map diagrams, translated to SBML qual (see Section 2.3), can be directly imported by tools like Cell Collective [293] or GINsim [46] for analysis. Preserving annotations and layout information ensures transparency and reusability of the models.

Importantly, Cell Collective is an online user-friendly modelling platform²⁶ that provides features for real-time *in silico* simulations and analysis of complex signalling networks. The platform allows users without computational background to simulate or analyse models to generate and prioritise new hypotheses. References and layout are used for model visualisation, supporting the interpretation of the results. The mathematics and code behind each model, however, remain accessible to all users. In turn, GINsim is a tool providing a wide range of analysis methods, including efficient identification of the states of convergence of a given model (attractors). Model reduction functionality can also be employed to facilitate the analysis of large-scale models.

Multiscale and stochastic computational modelling

Viral infection and immune response are complex processes that span many different scales, from molecular interactions to multicellular behaviour. The modelling and simulation of such complex scenarios require a dedicated multiscale computational architecture, where multiple models run in parallel and communicate among them to capture cellular behaviour and intercellular communications. Multiscale agent-based models simulate processes taking

²⁶ <https://cellcollective.org>

place at different time scales, e.g., diffusion, cell mechanics, cell cycle, or signal transduction [294], proposed also for COVID-19 [295]. PhysiBoSS [296] allows such simulation of intracellular processes by combining the computational framework of PhysiCell [297] with MaBoSS [298] tool for stochastic simulation of logical models to study of transient effects and perturbations [299]. Implementation of detailed COVID-19 signalling models in the PhysiBoSS framework may help to better understand complex dynamics of multi-scale processes as interactions and crosstalk between immune system components and the host cell in COVID-19.

4.3 Case study: RNA-Seq-based analysis of transcription factor (TF) activity

In this case study, we combine computational approaches discussed above and present results derived from omics data analysis on the COVID-19 Disease Maps diagrams. We measured the effect of COVID-19 at the transcription factor (TF) activity level by applying VIPER [300] combined with DoRothEA regulons [283] on RNA-seq datasets of the SARS-CoV-2 infected cell line [168]. Then, we mapped the TFs normalised enrichment score (NES) on the *Interferon type I signalling pathway* diagram of the COVID-19 Disease Map using the SIF files generated by CaSQ (see Section 2.3). As highlighted in Figure 4, our manually curated pathway included some of the most active TFs after SARS-CoV-2 infection, such as STAT1, STAT2, IRF9 and NFKB1. These genes are well known to be involved in cytokine signalling and first antiviral response [301,302]. Interestingly, they are located downstream of various viral proteins (*E*, *S*, *Nsp1*, *Orf7a* and *Orf3a*) and members of the MAPK pathway (*MAPK8*, *MAPK14* and *MAP3K7*). SARS-CoV-2 infection is known to promote MAPK activation, which mediates the cellular response to pathogenic infection and promotes the production of pro-inflammatory cytokines [281]. Altogether, we identified signaling events that may capture the mechanistic response of the human cells to the viral infection.




Figure 4: the *Interferon type I* signalling pathway diagram of the COVID-19 Disease Map integrated with TF activity derived from transcriptomics data after SARS-CoV-2 infection. A zoom was applied in the area containing the most active TFs (red nodes) after infection. Node shapes: host genes (rectangles), host molecular complex (octagons), viral proteins (V shape), drugs (diamonds) and phenotypes (triangles).

4.4 Case study: RNA-seq-based analysis of pathway signalling

In this use case, the Hipathia [289] algorithm was used to calculate the level of activity of the subpathways from the COVID-19 Apoptosis diagram, with the aim to evaluate whether COVID-19 Disease Map diagrams can be used for pathway modelling approach. To this end, a public RNA-seq dataset from human SARS-CoV-2 infected lung cells (GEO GSE147507) was used. First, the RNA-seq gene expression data was normalized with the Trimmed mean of M

values (TMM) normalization [303], then rescaled to range [0;1] for the calculation of the signal and normalised using quantile normalisation [304]. The normalised gene expression values were used to calculate the level of activation of the subpathways, then a case/control contrast with a Wilcoxon test was used to assess differences in signaling activity between the two conditions.




Figure 5. Representation of the activation level of Apoptosis pathway in SARS-CoV-2 infected lung cell lines. The activation levels have been calculated using transcriptional data from GSE147507 and Hipathia mechanistic pathway analysis algorithm. Each node represents a gene (ellipse), a metabolite (circle) or a function (square). The pathway is composed of circuits from a receptor gene/metabolite to an effector gene/function, with interactions simplified to inhibitions or activations (see Section 2.3, SIF format). Significantly deregulated circuits are highlighted by color arrows (red: activated in infected cells). The color of the node corresponds to the level of differential expression of each node in SARS-CoV-2 infected cells vs normal lung cells. Blue: down-regulated elements, red: up-regulated elements, white: elements with not statistically significant differential expression. Hipathia calculates the overall circuit activation, and can indicate deregulated interaction even if interacting elements are not individually differentially expressed.

Results of the Apoptosis pathway analysis can be seen in Figure 5 and Supplementary Material 5. Importantly, Hipathia calculates the overall activation of circuits (series of causally connected elements), and can indicate deregulated interactions resulting from a cumulative effect, even if interacting elements are not individually differentially expressed. When discussing differential activation, we refer to the circuits, while individual elements

are mentioned as differentially expressed. The analysis shows an overactivation of several circuits, specifically the one ending in the effector protein BAX. This overactivation seems to be led by the overexpression of the BAD protein, inhibiting BCL2-MCL1-BCL2L1 complex, which in turn inhibits BAX. Indeed, SARS-CoV-2 infection can invoke caspase8-induced apoptosis [305], where BAX together with the ripoptosome/caspase-8 complex, may act as a pro-inflammatory checkpoint [306]. This result is supported by studies in SARS-CoV, showing BAX overexpression following infection [121,307]. Overall, our findings recapitulate reported outcomes. With evolving contents of the COVID-19 Disease Map and new omics data becoming available, new mechanism-based hypotheses can be formulated.

4.5 Parallel efforts

In the COVID19 Disease Map community we strive to produce interoperable content and seamless downstream analyses, translating the graphic representations of the molecular mechanisms to executable models. We are also aware of parallel efforts towards modelling of COVID-19 mechanisms, which we plan to include as a part of our ecosystem. These efforts are not yet directly interoperable with the COVID 19 Disease Map content as they use either different notation schemes or require parameters not covered by our biocuration guidelines. At the same time, they provide a complementary source of information and the opportunity to create an even broader toolset to tackle the pandemic.

The modified Edinburgh Pathway Notation (mEPN) scheme [308] allows for the detailed visual encoding of molecular processes using the yEd platform but diagrams are constructed in such a way as to also function as Petri nets. These can then be used directly for activity simulations using the BioLayout network analysis tool [309]. The current mEPN COVID-19 model details the replication cycle of SARS-CoV-2, integrated with a range of host defence systems, e.g. type 1 interferon signalling, TLR receptors, OAS systems, etc. Simulations of altered gene expression, interactions with drug targets or changes to interaction kinetics can be represented by introducing relevant transitions or nodes directly in the diagram. Currently, models constructed in mEPN can be saved as SBGN.ml files, however is a loss of information and the features associated computationally are not compatible with other COVID-19 Disease Map diagrams (not modelled as Petri nets).

The COVID-19 Disease Map can support dynamic kinetic modelling to quantify the behaviour of different pathways and evaluate the dynamic effects of perturbations. However, it is necessary to assign a kinetic equation or a rate law to every reaction in the diagram to be analysed. This process is challenging because any given reaction depends on its cellular and physiological context, which makes it difficult to parameterise. Software support of tools like SBMLsqueezer [21] and reaction kinetics databases like SABIO-RK [310] are indispensable in this effort. Nevertheless, the most critical factor is the availability of experimentally validated parameters that can be reliably applied in SARS-CoV-2 modelling scenarios.

5. Discussion

The COVID-19 Disease Map is both a knowledgebase and a computational repository. On the one hand, it is a graphical, interactive representation of disease-relevant molecular mechanisms linking many knowledge sources. On the other hand, it is a computational resource of curated content for graph-based analyses and disease modelling. It offers a shared mental map for understanding the dynamic nature of the disease at the molecular level and also its dynamic propagation at a systemic level. Thus, it provides a platform for a precise formulation of models, accurate data interpretation, monitoring of therapy, and potential for drug repositioning.

The COVID-19 Disease Map spans three platforms and assembles diagrams describing molecular mechanisms of COVID-19. These diagrams are grounded in the relevant published SARS-CoV-2 research, completed where necessary by mechanisms discovered in related beta-coronaviruses. This unprecedented effort of community-driven biocuration resulted in over forty diagrams with molecular resolution constructed since March 2020. It demonstrates that expertise in biocuration, clear guidelines and text mining solutions can accelerate the passage from the published findings to a meaningful mechanistic representation of knowledge. The COVID 19 Disease Map can provide the tipping point to shortcut research data generation and knowledge accumulation, creating a formalized and standardized streamline of well defined tasks.

This approach to an emerging pandemic leveraged the capacity and expertise of an entire swath of the bioinformatics community, bringing them together to improve the way we build and share knowledge. By aligning our efforts, we strive to provide COVID-19 specific pathway models, synchronize content with similar resources and encourage discussion and feedback at every stage of the curation process. With new results published every day, and with the active engagement of the research community, we envision the COVID-19 Disease Map as an evolving and continuously updated knowledge base whose utility spans the entire research and development spectrum from basic science to pharmaceutical development and personalized medicine.

Moreover, our approach includes a large-scale effort to create interoperable tools and seamless downstream analysis pipelines to boost the applicability of established methodologies to the COVID-19 Disease Map content. This includes harmonisation of formats, support of standards, and transparency in all steps to ensure wide use and content reusability. Preliminary results of such efforts are presented in the case studies.

The COVID-19 Disease Map Community is open and expanding as more people with complementary expertise join forces. In the longer run, the map's content will help to find robust signatures related to SARS-CoV-2 predisposition or response to various treatments, along with the prioritization of new potential drug targets or drug candidates. We aim to

provide the tools to deepen our understanding of the mechanisms driving the infection and help boost drug development supported with testable suggestions. We aim at building armor for new treatments to prevent new waves of COVID-19 or similar pandemics.

Authors' contributions

M. Ostaszewski, A. Niarakis, A. Mazein and I. Kuperstein planned and coordinated the project
R. Phair, A. Orta-Resendiz, J-M. Ravel, R. Fraser, V. Ortseifen and S. Marchesi advised the project as domain experts

V. Singh, S.S. Aghamiri, M.L. Acencio, E. Glaab, A. Ruepp, G. Fobo, C. Montrone, B. Brauner, G. Frischman, L.C.M. Gomez, J. Sommers, M. Hoch, S. Gupta, J. Scheel, H. Borlinghaus, T. Czauderna, F. Schreiber, A. Montagud, M. Ponce de Leon, A. Funahashi, Y. Hiki, N. Hiroi, T.G. Yamada, A. Dräger, A. Renz, M. Naveez, Z. Bocskei, F. Messina, D. Börnigen, L. Fergusson, M. Conti, M. Rameil, V. Nakonecnij, J. Vanhoefer, L. Schmiester, M. Wang, E.E. Ackerman, J. Shoemaker, J. Zucker, K. Oxford, J. Teuton, E. Kocakaya, G.Y. Summak, K. Hanspers, M. Kutmon, S. Coort, L. Eijssen, F. Erhart, D.A.B. Rex, D. Slenter, M. Martens, R. Haw, B. Jassal, L. Matthews, M. Orlic-Milacic, A.S. Ribeiro, K. Rothfels, V. Shamovsky, R. Stephan, C. Sevilla and T. Varusai curated and reviewed the diagrams;

P. Gawron, E. Smula, L. Heirendt, V. Satagopam, G. Wu, A. Riutta, M. Golebiewski, S. Owen, C. Goble and X. Hu designed, developed and implemented key elements of the data sharing and communication infrastructure;

RW. Owen, D. Maier, A. Bauch, B.M. Gyori, J.A. Bauch, C. Vega, V. Groues, M. Vazquez, P. Porras, L. Licata, M. Ianucelli, F. Sacco, A. Nestorova, A. Yuryev, A. de Waard designed and developed the contents of interaction and pathway databases, and text mining platforms and their visualisation and interoperability functionalities;

D. Turei, A. Luna, O. Babur, S. Soliman, A. Valdeolivas, M. Esteban, M. Pena, T. Helikar, B.L. Puniya, D. Modos, A. Treveil, M. Olbei, B. De Meulder, A. Dugourd, A. Naldi, V. Noel, L. Calzone developed format interoperability, analysis and modelling workflows;

C. Sander, E. Demir, T. Korcsmaros, T. Freeman, F. Augé, J.S. Beckmann, J. Hasenauer, O. Wolkenhauer, E.L. Wilighagen, A.R. Pico, C.T. Evelo, M.E. Gillespie, L. Stein, H. Hermjakob, P. D'Eustachio, J. Saez-Rodriguez, J. Dopazo, A. Valencia, H. Kitano, E. Barillot, C. Auffray, R. Balling, R. Schneider defined the strategy and scope of the project and revised its progress;

M. Ostaszewski, A. Niarakis, A. Mazein and I. Kuperstein wrote the manuscript;

A. Orta-Resendiz, I. Kuperstein and A. Mazein designed the overview figures;

All authors have revised, read and accepted the manuscript in its final form.

Acknowledgements

We would like to thank Andjela Tatarovic, architect, and Gina Crovetto, researcher in the field of cancer, for their help with the design of the top-level view diagrams. We would like to acknowledge the Responsible and Reproducible Research (R3) team of the Luxembourg Centre for Systems Biomedicine for supporting the project and providing necessary communication and data sharing resources. The work presented in this paper was carried out using the ELIXIR Luxembourg tools and services.

Supplementary Materials

Supplementary Material 1: COVID-19 Disease Map diagrams

Supplementary Material 2: Biocuration platforms and formats

Supplementary Material 3: Description of bioinformatic resources

Supplementary Material 4: Results of the Hipathia analysis of the Apoptosis pathway

Bibliography

1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579:270–3.
2. Gagliardi I, Patella G, Michael A, Serra R, Provenzano M, Andreucci M. COVID-19 and the Kidney: From Epidemiology to Clinical Practice. *J Clin Med*. 2020;9.
3. Ziegler CGK, Allon SJ, Nyquist SK, Mbanjo IM, Miao VN, Tzouanas CN, et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. *Cell*. 2020;181:1016-1035.e19.
4. Ostaszewski M, Mazein A, Gillespie ME, Kuperstein I, Niarakis A, Hermjakob H, et al. COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms. *Sci Data*. 2020;7:136.
5. Mazein A, Ostaszewski M, Kuperstein I, Watterson S, Le Novère N, Lefaudeux D, et al. Systems medicine disease maps: community-driven comprehensive representation of disease mechanisms. *NPJ Syst Biol Appl*. 2018;4:21.

6. Ostaszewski M, Gebel S, Kuperstein I, Mazein A, Zinovyev A, Dogrusoz U, et al. Community-driven roadmap for integrated disease maps. *Brief Bioinform.* 2019;20:659–70.
7. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, et al. The Reactome Pathway Knowledgebase. *Nucleic Acids Res.* 2020;48:D498–503.
8. Slenter DN, Kutmon M, Hanspers K, Riutta A, Windsor J, Nunes N, et al. WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research. *Nucleic Acids Res.* 2018;46:D661–7.
9. Le Novère N, Hucka M, Mi H, Moodie S, Schreiber F, Sorokin A, et al. The Systems Biology Graphical Notation. *Nat Biotechnol.* 2009;27:735–41.
10. Keating SM, Waltemath D, König M, Zhang F, Dräger A, Chaouiya C, et al. SBML Level 3: an extensible format for the exchange and reuse of biological models. *Mol Syst Biol.* 2020;16:e9110.
11. Demir E, Cary MP, Paley S, Fukuda K, Lemer C, Vastrik I, et al. The BioPAX community standard for pathway data sharing. *Nat Biotechnol.* 2010;28:935–42.
12. Wimalaratne SM, Juty N, Kunze J, Janée G, McMurry JA, Beard N, et al. Uniform resolution of compact identifiers for biomedical data. *Sci Data.* 2018;5:180029.
13. Türei D, Korcsmáros T, Saez-Rodriguez J. OmniPath: guidelines and gateway for literature-curated signaling pathway resources. *Nat Methods.* 2016;13:966–7.
14. Perfetto L, Pastrello C, Del-Toro N, Duesbury M, Iannuccelli M, Kotlyar M, et al. The IMEx Coronavirus interactome: an evolving map of Coronaviridae-Host molecular interactions. *BioRxiv Prepr Serv Biol.* 2020;
15. Licata L, Lo Surdo P, Iannuccelli M, Palma A, Micarelli E, Perfetto L, et al. SIGNOR 2.0, the SIGNaling Network Open Resource 2.0: 2019 update. *Nucleic Acids Res.* 2020;48:D504–10.
16. Rodchenkov I, Babur O, Luna A, Aksoy BA, Wong JV, Fong D, et al. Pathway Commons 2019 Update: integration, analysis and exploration of pathway data. *Nucleic Acids Res.* 2020;48:D489–97.
17. Wolstencroft K, Krebs O, Snoep JL, Stanford NJ, Bacall F, Golebiewski M, et al. FAIRDOMHub: a repository and collaboration environment for sharing systems biology research. *Nucleic Acids Res.* 2017;45:D404–7.
18. Juty N, Le Novère N, Laibe C. Identifiers.org and MIRIAM Registry: community resources to provide persistent identification. *Nucleic Acids Res.* 2012;40:D580-586.
19. Niarakis A, Kuiper M, Ostaszewski M, Malik Sheriff RS, Casals-Casas C, Thieffry D, et al.

Setting the basis of best practices and standards for curation and annotation of logical models in biology-highlights of the [BC]2 2019 CoLoMoTo/SysMod Workshop. *Brief Bioinform.* 2020;

20. Römer M, Eichner J, Dräger A, Wrzodek C, Wrzodek F, Zell A. ZBIT Bioinformatics Toolbox: A Web-Platform for Systems Biology and Expression Data Analysis. *PloS One.* 2016;11:e0149263.

21. Dräger A, Zielinski DC, Keller R, Rall M, Eichner J, Palsson BO, et al. SBMLsqueezer 2: context-sensitive creation of kinetic equations in biochemical networks. *BMC Syst Biol.* 2015;9:68.

22. Gawron P, Ostaszewski M, Satagopam V, Gebel S, Mazein A, Kuzma M, et al. MINERVA-a platform for visualization and curation of molecular interaction networks. *NPJ Syst Biol Appl.* 2016;2:16020.

23. Czauderna T, Klukas C, Schreiber F. Editing, validating and translating of SBGN maps. *Bioinforma Oxf Engl.* 2010;26:2340–1.

24. Kutmon M, van Iersel MP, Bohler A, Kelder T, Nunes N, Pico AR, et al. PathVisio 3: an extendable pathway analysis toolbox. *PLoS Comput Biol.* 2015;11:e1004085.

25. Matsuoka Y, Funahashi A, Ghosh S, Kitano H. Modeling and simulation using CellDesigner. *Methods Mol Biol Clifton NJ.* 2014;1164:121–45.

26. van Iersel MP, Villéger AC, Czauderna T, Boyd SE, Bergmann FT, Luna A, et al. Software support for SBGN maps: SBGN-ML and LibSBGN. *Bioinforma Oxf Engl.* 2012;28:2016–21.

27. Bergmann FT, Czauderna T, Dogrusoz U, Rougny A, Dräger A, Touré V, et al. Systems biology graphical notation markup language (SBGNML) version 0.3. *J Integr Bioinforma.* 2020;17.

28. Lu Wang L, Lo K, Chandrasekhar Y, Reas R, Yang J, Eide D, et al. CORON-19: The Covid-19 Open Research Dataset. *ArXiv.* 2020;

29. Orchard S, Kerrien S, Abbani S, Aranda B, Bhate J, Bidwell S, et al. Protein interaction data curation: the International Molecular Exchange (IMEx) consortium. *Nat Methods.* 2012;9:345–50.

30. Hanspers K, Riutta A, Kutmon M, Pico AR. 25 Years of Pathway Figures [Internet]. *Bioinformatics;* 2020 May. Available from: <http://biorxiv.org/lookup/doi/10.1101/2020.05.29.124503>

31. Bauch A, Pellet J, Schleicher T, Yu X, Gelemanović A, Cristella C, et al. Informing epidemic

(research) responses in a timely fashion by knowledge management - a Zika virus use case [Internet]. Pathology; 2020 Apr. Available from: <http://biorxiv.org/lookup/doi/10.1101/2020.04.17.044743>

32. Gyori BM, Bachman JA, Subramanian K, Muhlich JL, Galescu L, Sorger PK. From word models to executable models of signaling networks using automated assembly. *Mol Syst Biol.* 2017;13:954.

33. Wei C-H, Kao H-Y, Lu Z. GNormPlus: An Integrative Approach for Tagging Genes, Gene Families, and Protein Domains. *BioMed Res Int.* 2015;2015:1-7.

34. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature.* 2020;583:459-68.

35. Vega C, Grouès V, Ostaszewski M, Schneider R, Satagopam V. BioKC: a collaborative platform for systems biology model curation and annotation [Internet]. *Systems Biology;* 2020 Oct. Available from: <http://biorxiv.org/lookup/doi/10.1101/2020.10.01.322438>

36. Zhang F, Smith LP, Blinov ML, Faeder J, Hlavacek WS, Juan Tapia J, et al. Systems biology markup language (SBML) level 3 package: multistate, multicomponent and multicompartments species, version 1, release 2. *J Integr Bioinforma.* 2020;17.

37. Gauges R, Rost U, Sahle S, Wengler K, Bergmann FT. The Systems Biology Markup Language (SBML) Level 3 Package: Layout, Version 1 Core. *J Integr Bioinforma.* 2015;12:267.

38. Bergmann FT, Keating SM, Gauges R, Sahle S, Wengler K. SBML Level 3 package: Render, Version 1, Release 1. *J Integr Bioinforma.* 2018;15.

39. Courtot M, Juty N, Knüpfer C, Waltemath D, Zhukova A, Dräger A, et al. Controlled vocabularies and semantics in systems biology. *Mol Syst Biol.* 2011;7:543.

40. Hoksza D, Gawron P, Ostaszewski M, Hasenauer J, Schneider R. Closing the gap between formats for storing layout information in systems biology. *Brief Bioinform.* 2020;21:1249-60.

41. Balaur I, Roy L, Mazein A, Karaca SG, Dogrusoz U, Barillot E, et al. cd2sbgmml: bidirectional conversion between CellDesigner and SBGN formats. *Bioinforma Oxf Engl.* 2020;36:2620-2.

42. Bohler A, Wu G, Kutmon M, Pradhana LA, Coort SL, Hanspers K, et al. Reactome from a WikiPathways Perspective. *PLoS Comput Biol.* 2016;12:e1004941.

43. Chaouiya C, Bérenguier D, Keating SM, Naldi A, van Iersel MP, Rodriguez N, et al. SBML qualitative models: a model representation format and infrastructure to foster interactions

between qualitative modelling formalisms and tools. *BMC Syst Biol.* 2013;7:135.

44. Aghamiri SS, Singh V, Naldi A, Helikar T, Soliman S, Niarakis A. Automated inference of Boolean models from molecular interaction maps using CaSQ. *Bioinforma Oxf Engl.* 2020;36:4473–82.

45. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* 2003;13:2498–504.

46. Naldi A, Hernandez C, Abou-Jaoudé W, Monteiro PT, Chaouiya C, Thieffry D. Logical Modeling and Analysis of Cellular Regulatory Networks With GINsim 3.0. *Front Physiol.* 2018;9:646.

47. Pillich RT, Chen J, Rynkov V, Welker D, Pratt D. NDEx: A Community Resource for Sharing and Publishing of Biological Networks. *Methods Mol Biol Clifton NJ.* 2017;1558:271–301.

48. Fung TS, Liu DX. Human Coronavirus: Host-Pathogen Interaction. *Annu Rev Microbiol.* 2019;73:529–57.

49. Chu H, Chan JF-W, Wang Y, Yuen TT-T, Chai Y, Hou Y, et al. Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2020;71:1400–9.

50. Hui KPY, Cheung M-C, Perera RAPM, Ng K-C, Bui CHT, Ho JCW, et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. *Lancet Respir Med.* 2020;8:687–95.

51. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. *Eur Respir J.* 2020;55.

52. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. *Lancet Infect Dis.* 2020;20:1135–40.

53. Davidson AM, Wysocki J, Batlle D. Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications. *Hypertens Dallas Tex 1979.* 2020;76:1339–49.

54. Swiecki M, Colonna M. Type I interferons: diversity of sources, production pathways and effects on immune responses. *Curr Opin Virol.* 2011;1:463–75.

55. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science*. 2020;369:718–24.
56. Sa Ribero M, Jouvenet N, Dreux M, Nisole S. Interplay between SARS-CoV-2 and the type I interferon response. *PLoS Pathog*. 2020;16:e1008737.
57. Lee JS, Shin E-C. The type I interferon response in COVID-19: implications for treatment. *Nat Rev Immunol*. 2020;20:585–6.
58. Park A, Iwasaki A. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. *Cell Host Microbe*. 2020;27:870–8.
59. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med*. 2020;172:577–82.
60. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med*. 2020;26:672–5.
61. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet Lond Engl*. 2020;395:497–506.
62. Bajema KL, Oster AM, McGovern OL, Lindstrom S, Stenger MR, Anderson TC, et al. Persons Evaluated for 2019 Novel Coronavirus - United States, January 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69:166–70.
63. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet Lond Engl*. 2020;395:507–13.
64. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020;323:1061–9.
65. Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. *Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg*. 2020;163:3–11.
66. Zhang R, Li Y, Zhang AL, Wang Y, Molina MJ. Identifying airborne transmission as the dominant route for the spread of COVID-19. *Proc Natl Acad Sci U S A*. 2020;117:14857–63.
67. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *N Engl J Med*.

2020;382:1564–7.

68. Klompas M, Baker MA, Rhee C. Airborne Transmission of SARS-CoV-2: Theoretical Considerations and Available Evidence. *JAMA*. 2020;

69. Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. Cell entry mechanisms of SARS-CoV-2. *Proc Natl Acad Sci U S A*. 2020;117:11727–34.

70. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature*. 2020;581:215–20.

71. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020;181:271-280.e8.

72. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol*. 2020;5:562–9.

73. Amraie R, Napoleon MA, Yin W, Berrigan J, Suder E, Zhao G, et al. CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2 and are differentially expressed in lung and kidney epithelial and endothelial cells. *BioRxiv Prepr Serv Biol*. 2020;

74. Gao C, Zeng J, Jia N, Stavenhagen K, Matsumoto Y, Zhang H, et al. SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors. *BioRxiv Prepr Serv Biol*. 2020;

75. Hoffmann M, Kleine-Weber H, Pöhlmann S. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol Cell*. 2020;78:779-784.e5.

76. Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. *Cell Mol Immunol*. 2020;17:765–7.

77. Nakagawa K, Lokugamage KG, Makino S. Viral and Cellular mRNA Translation in Coronavirus-Infected Cells. *Adv Virus Res*. 2016;96:165–92.

78. Gosert R, Kanjanahaluethai A, Egger D, Bienz K, Baker SC. RNA replication of mouse hepatitis virus takes place at double-membrane vesicles. *J Virol*. 2002;76:3697–708.

79. Harcourt BH, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson KM, Smith CM, et al. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. *J Virol*. 2004;78:13600–12.

80. Chen S, Jonas F, Shen C, Hilgenfeld R, Higenfeld R. Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode. *Protein Cell*. 2010;1:59–74.

81. V'kovski P, Gerber M, Kelly J, Pfaender S, Ebert N, Braga Lagache S, et al. Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling. *eLife*. 2019;8.
82. Angelini MM, Akhlaghpour M, Neuman BW, Buchmeier MJ. Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles. *mBio*. 2013;4.
83. Sawicki SG, Sawicki DL. Coronaviruses use discontinuous extension for synthesis of subgenome-length negative strands. *Adv Exp Med Biol*. 1995;380:499–506.
84. Hagemeyer MC, Vonk AM, Monastyrska I, Rottier PJM, de Haan CAM. Visualizing coronavirus RNA synthesis in time by using click chemistry. *J Virol*. 2012;86:5808–16.
85. Snijder EJ, Limpens RWAL, de Wilde AH, de Jong AWM, Zevenhoven-Dobbe JC, Maier HJ, et al. A unifying structural and functional model of the coronavirus replication organelle: Tracking down RNA synthesis. *PLoS Biol*. 2020;18:e3000715.
86. Versteeg GA, Bredenbeek PJ, van den Worm SHE, Spaan WJM. Group 2 coronaviruses prevent immediate early interferon induction by protection of viral RNA from host cell recognition. *Virology*. 2007;361:18–26.
87. Grootjans J, Kaser A, Kaufman RJ, Blumberg RS. The unfolded protein response in immunity and inflammation. *Nat Rev Immunol*. 2016;16:469–84.
88. Sureda A, Alizadeh J, Nabavi SF, Berindan-Neagoe I, Cismaru CA, Jeandet P, et al. Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management? *Eur J Pharmacol*. 2020;882:173288.
89. Oakes SA, Papa FR. The role of endoplasmic reticulum stress in human pathology. *Annu Rev Pathol*. 2015;10:173–94.
90. Senft D, Ronai ZA. UPR, autophagy, and mitochondria crosstalk underlies the ER stress response. *Trends Biochem Sci*. 2015;40:141–8.
91. Fukushi M, Yoshinaka Y, Matsuoka Y, Hatakeyama S, Ishizaka Y, Kirikae T, et al. Monitoring of S protein maturation in the endoplasmic reticulum by calnexin is important for the infectivity of severe acute respiratory syndrome coronavirus. *J Virol*. 2012;86:11745–53.
92. Krähling V, Stein DA, Spiegel M, Weber F, Mühlberger E. Severe acute respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity. *J Virol*. 2009;83:2298–309.

93. DeDiego ML, Nieto-Torres JL, Jiménez-Guardeño JM, Regla-Nava JA, Alvarez E, Oliveros JC, et al. Severe acute respiratory syndrome coronavirus envelope protein regulates cell stress response and apoptosis. *PLoS Pathog.* 2011;7:e1002315.
94. Choi Y, Bowman JW, Jung JU. Autophagy during viral infection - a double-edged sword. *Nat Rev Microbiol.* 2018;16:341–54.
95. Yang J, Zhou R, Ma Z. Autophagy and Energy Metabolism. *Adv Exp Med Biol.* 2019;1206:329–57.
96. Bello-Perez M, Sola I, Novoa B, Klionsky DJ, Falco A. Canonical and Noncanonical Autophagy as Potential Targets for COVID-19. *Cells.* 2020;9.
97. Carmona-Gutierrez D, Bauer MA, Zimmermann A, Kainz K, Hofer SJ, Kroemer G, et al. Digesting the crisis: autophagy and coronaviruses. *Microb Cell Graz Austria.* 2020;7:119–28.
98. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. *Virology.* 2020;35:266–71.
99. Zhang H, Tu J, Cao C, Yang T, Gao L. Proteasome activator PA28 γ -dependent degradation of coronavirus disease (COVID-19) nucleocapsid protein. *Biochem Biophys Res Commun.* 2020;529:251–6.
100. Reggiori F, Monastyrska I, Verheije MH, Calì T, Ulasli M, Bianchi S, et al. Coronaviruses Hijack the LC3-I-positive Endosomes, ER-derived vesicles exporting short-lived ERAD regulators, for replication. *Cell Host Microbe.* 2010;7:500–8.
101. Prentice E, Jerome WG, Yoshimori T, Mizushima N, Denison MR. Coronavirus replication complex formation utilizes components of cellular autophagy. *J Biol Chem.* 2004;279:10136–41.
102. Zhao Z, Thackray LB, Miller BC, Lynn TM, Becker MM, Ward E, et al. Coronavirus replication does not require the autophagy gene ATG5. *Autophagy.* 2007;3:581–5.
103. Cottam EM, Whelband MC, Wileman T. Coronavirus NSP6 restricts autophagosome expansion. *Autophagy.* 2014;10:1426–41.
104. Benvenuto D, Angeletti S, Giovanetti M, Bianchi M, Pascarella S, Cauda R, et al. Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy. *J Infect.* 2020;81:e24–7.
105. Yang N, Shen H-M. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19. *Int J Biol Sci.* 2020;16:1724–31.
106. Shojaei S, Suresh M, Klionsky DJ, Labouta HI, Ghavami S. Autophagy and SARS-CoV-2

- infection: A possible smart targeting of the autophagy pathway. *Virulence*. 2020;11:805–10.
107. Brest P, Benzaquen J, Klionsky DJ, Hofman P, Mograbi B. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype? *Autophagy*. 2020;1–4.
108. Hannan MA, Rahman MA, Rahman MS, Sohag AAM, Dash R, Hossain KS, et al. Intermittent fasting, a possible priming tool for host defense against SARS-CoV-2 infection: Crosstalk among calorie restriction, autophagy and immune response. *Immunol Lett*. 2020;226:38–45.
109. Chen C-J, Makino S. Murine coronavirus-induced apoptosis in 17Cl-1 cells involves a mitochondria-mediated pathway and its downstream caspase-8 activation and bid cleavage. *Virology*. 2002;302:321–32.
110. Chen Y, Feng Z, Diao B, Wang R, Wang G, Wang C, et al. The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes [Internet]. *Infectious Diseases (except HIV/AIDS)*; 2020 Mar. Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.03.27.20045427>
111. Chu H, Zhou J, Wong BH-Y, Li C, Chan JF-W, Cheng Z-S, et al. Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways. *J Infect Dis*. 2016;213:904–14.
112. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. *Cell*. 2000;102:1–4.
113. Elmore S. Apoptosis: a review of programmed cell death. *Toxicol Pathol*. 2007;35:495–516.
114. Diemer C, Schneider M, Schätzl HM, Gilch S. Modulation of Host Cell Death by SARS Coronavirus Proteins. In: Lal SK, editor. *Mol Biol SARS-Coronavirus* [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2010 [cited 2020 Oct 22]. p. 231–45. Available from: http://link.springer.com/10.1007/978-3-642-03683-5_14
115. Liu M, Yang Y, Gu C, Yue Y, Wu KK, Wu J, et al. Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calcium-independent protein kinase C pathways. *FASEB J Off Publ Fed Am Soc Exp Biol*. 2007;21:1586–96.
116. Kanzawa N, Nishigaki K, Hayashi T, Ishii Y, Furukawa S, Niino A, et al. Augmentation of chemokine production by severe acute respiratory syndrome coronavirus 3a/X1 and 7a/X4 proteins through NF-kappaB activation. *FEBS Lett*. 2006;580:6807–12.
117. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. *Mol Cell Biol*. 1997;17:1595–606.

118. Mizutani T, Fukushi S, Saijo M, Kurane I, Morikawa S. JNK and PI3k/Akt signaling pathways are required for establishing persistent SARS-CoV infection in Vero E6 cells. *Biochim Biophys Acta*. 2005;1741:4–10.
119. Abreu MT, Arnold ET, Chow JY, Barrett KE. Phosphatidylinositol 3-kinase-dependent pathways oppose Fas-induced apoptosis and limit chloride secretion in human intestinal epithelial cells. Implications for inflammatory diarrheal states. *J Biol Chem*. 2001;276:47563–74.
120. Gauthier R, Harnois C, Drolet JF, Reed JC, Vézina A, Vachon PH. Human intestinal epithelial cell survival: differentiation state-specific control mechanisms. *Am J Physiol Cell Physiol*. 2001;280:C1540-1554.
121. Tan Y-X, Tan THP, Lee MJ-R, Tham P-Y, Gunalan V, Druce J, et al. Induction of apoptosis by the severe acute respiratory syndrome coronavirus 7a protein is dependent on its interaction with the Bcl-XL protein. *J Virol*. 2007;81:6346–55.
122. Tsoi H, Li L, Chen ZS, Lau K-F, Tsui SKW, Chan HYE. The SARS-coronavirus membrane protein induces apoptosis via interfering with PDK1-PKB/Akt signalling. *Biochem J*. 2014;464:439–47.
123. Wong HYF, Lam HYS, Fong AH-T, Leung ST, Chin TW-Y, Lo CSY, et al. Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19. *Radiology*. 2020;296:E72–8.
124. Bao C, Liu X, Zhang H, Li Y, Liu J. Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis. *J Am Coll Radiol JACR*. 2020;17:701–9.
125. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. *Clin Immunol Orlando Fla*. 2020;215:108427.
126. Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. *N Engl J Med*. 2017;377:562–72.
127. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest*. 2020;130:2620–9.
128. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. *Nature*. 2020;584:463–9.
129. Sinha P, Matthay MA, Calfee CS. Is a “Cytokine Storm” Relevant to COVID-19? *JAMA Intern Med*. 2020;
130. Quartuccio L, Semerano L, Benucci M, Boissier M-C, De Vita S. Urgent avenues in the

treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome. *Joint Bone Spine*. 2020;87:191–3.

131. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D a. MPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. 2020;191:145–7.

132. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost JTH*. 2020;18:844–7.

133. Wang D, Yin Y, Hu C, Liu X, Zhang X, Zhou S, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. *Crit Care Lond Engl*. 2020;24:188.

134. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. *Crit Care Lond Engl*. 2020;24:360.

135. Urwyler P, Moser S, Charitos P, Heijnen IAFM, Rudin M, Sommer G, et al. Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System. *Front Immunol*. 2020;11:2072.

136. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. *Transl Res J Lab Clin Med*. 2020;220:1–13.

137. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. *Clin Chem Lab Med*. 2020;58:1021–8.

138. Henry BM, Vikse J, Benoit S, Favalaro EJ, Lippi G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. *Clin Chim Acta Int J Clin Chem*. 2020;507:167–73.

139. Koka V, Huang XR, Chung ACK, Wang W, Truong LD, Lan HY. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. *Am J Pathol*. 2008;172:1174–83.

140. Dalpiaz PLM, Lamas AZ, Caliman IF, Ribeiro RF, Abreu GR, Moyses MR, et al. Sex Hormones Promote Opposite Effects on ACE and ACE2 Activity, Hypertrophy and Cardiac Contractility in Spontaneously Hypertensive Rats. *PloS One*. 2015;10:e0127515.

141. Fernández-Atucha A, Izagirre A, Fraile-Bermúdez AB, Kortajarena M, Larrinaga G, Martínez-Lage P, et al. Sex differences in the aging pattern of renin-angiotensin system serum peptidases. *Biol Sex Differ.* 2017;8:5.
142. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J-C, Turner AJ, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. *Circ Res.* 2020;126:1456–74.
143. Paz Ocaranza M, Riquelme JA, García L, Jalil JE, Chiong M, Santos RAS, et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. *Nat Rev Cardiol.* 2020;17:116–29.
144. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci.* 2020;63:364–74.
145. McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. *Circ Res.* 2020;127:571–87.
146. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. *Clin Microbiol Rev.* 2009;22:240–73, Table of Contents.
147. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. *Cell.* 2010;140:805–20.
148. Siu K-L, Kok K-H, Ng M-HJ, Poon VKM, Yuen K-Y, Zheng B-J, et al. Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. *J Biol Chem.* 2009;284:16202–9.
149. Liao Q-J, Ye L-B, Timani KA, Zeng Y-C, She Y-L, Ye L, et al. Activation of NF-kappaB by the full-length nucleocapsid protein of the SARS coronavirus. *Acta Biochim Biophys Sin.* 2005;37:607–12.
150. Li S-W, Wang C-Y, Jou Y-J, Huang S-H, Hsiao L-H, Wan L, et al. SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6. *Int J Mol Sci.* 2016;17.
151. Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. *Antiviral Res.* 2020;179:104811.
152. Kuri T, Zhang X, Habjan M, Martínez-Sobrido L, García-Sastre A, Yuan Z, et al. Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation. *J Gen Virol.* 2009;90:2686–94.

153. Su S, Jiang S. A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2. *Signal Transduct Target Ther.* 2020;5:71.
154. Lokugamage KG, Hage A, de Vries M, Valero-Jimenez AM, Schindewolf C, Dittmann M, et al. SARS-CoV-2 is sensitive to type I interferon pretreatment. *BioRxiv Prepr Serv Biol.* 2020;
155. Frieman M, Yount B, Heise M, Kopecky-Bromberg SA, Palese P, Baric RS. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. *J Virol.* 2007;81:9812–24.
156. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science.* 2020;
157. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. *Science.* 2020;
158. Lim YX, Ng YL, Tam JP, Liu DX. Human Coronaviruses: A Review of Virus-Host Interactions. *Dis Basel Switz.* 2016;4.
159. Devaraj SG, Wang N, Chen Z, Chen Z, Tseng M, Barretto N, et al. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. *J Biol Chem.* 2007;282:32208–21.
160. Kopecky-Bromberg SA, Martínez-Sobrido L, Frieman M, Baric RA, Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. *J Virol.* 2007;81:548–57.
161. Fung TS, Liu DX. Post-translational modifications of coronavirus proteins: roles and function. *Future Virol.* 2018;13:405–30.
162. Liu DX, Fung TS, Chong KK-L, Shukla A, Hilgenfeld R. Accessory proteins of SARS-CoV and other coronaviruses. *Antiviral Res.* 2014;109:97–109.
163. Minakshi R, Padhan K, Rani M, Khan N, Ahmad F, Jameel S. The SARS Coronavirus 3a Protein Causes Endoplasmic Reticulum Stress and Induces Ligand-Independent Downregulation of the Type 1 Interferon Receptor. Ahmed N, editor. *PLoS ONE.* 2009;4:e8342.
164. Wong HH, Fung TS, Fang S, Huang M, Le MT, Liu DX. Accessory proteins 8b and 8ab of severe acute respiratory syndrome coronavirus suppress the interferon signaling pathway by mediating ubiquitin-dependent rapid degradation of interferon regulatory factor 3. *Virology.* 2018;515:165–75.

165. Maringer K, Fernandez-Sesma A. Message in a bottle: lessons learned from antagonism of STING signalling during RNA virus infection. *Cytokine Growth Factor Rev.* 2014;25:669–79.
166. Ding S, Robek MD. Peroxisomal MAVS activates IRF1-mediated IFN- λ production. *Nat Immunol.* 2014;15:700–1.
167. Berthelot J-M, Lioté F. COVID-19 as a STING disorder with delayed over-secretion of interferon-beta. *EBioMedicine.* 2020;56:102801.
168. Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Uhl S, Hoagland D, Møller R, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell.* 2020;181:1036-1045.e9.
169. Lazear HM, Nice TJ, Diamond MS. Interferon- λ : Immune Functions at Barrier Surfaces and Beyond. *Immunity.* 2015;43:15–28.
170. Mesev EV, LeDesma RA, Ploss A. Decoding type I and III interferon signalling during viral infection. *Nat Microbiol.* 2019;4:914–24.
171. Thoms M, Buschauer R, Ameismeier M, Koepke L, Denk T, Hirschenberger M, et al. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2 [Internet]. *Molecular Biology*; 2020 May. Available from: <http://biorxiv.org/lookup/doi/10.1101/2020.05.18.102467>
172. Rao M, Dodoo E, Zumla A, Maeurer M. Immunometabolism and Pulmonary Infections: Implications for Protective Immune Responses and Host-Directed Therapies. *Front Microbiol.* 2019;10:962.
173. Kedia-Mehta N, Finlay DK. Competition for nutrients and its role in controlling immune responses. *Nat Commun.* 2019;10:2123.
174. Zhang X, Ding M, Zhu P, Huang H, Zhuang Q, Shen J, et al. New Insights into the Nrf-2/HO-1 Signaling Axis and Its Application in Pediatric Respiratory Diseases. *Oxid Med Cell Longev.* 2019;2019:3214196.
175. Wu B, Wu Y, Tang W. Heme Catabolic Pathway in Inflammation and Immune Disorders. *Front Pharmacol.* 2019;10:825.
176. Batra N, De Souza C, Batra J, Raetz AG, Yu A-M. The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19). *Int J Mol Sci.* 2020;21:6412.
177. Ryter SW. Bile pigments in pulmonary and vascular disease. *Front Pharmacol.*

2012;3:39.

178. Vitali SH, Fernandez-Gonzalez A, Nadkarni J, Kwong A, Rose C, Mitsialis SA, et al. Heme oxygenase-1 dampens the macrophage sterile inflammasome response and regulates its components in the hypoxic lung. *Am J Physiol Lung Cell Mol Physiol*. 2020;318:L125–34.

179. Jung S-S, Moon J-S, Xu J-F, Ifedigbo E, Ryter SW, Choi AMK, et al. Carbon monoxide negatively regulates NLRP3 inflammasome activation in macrophages. *Am J Physiol Lung Cell Mol Physiol*. 2015;308:L1058-1067.

180. Lv J, Su W, Yu Q, Zhang M, Di C, Lin X, et al. Heme oxygenase-1 protects airway epithelium against apoptosis by targeting the proinflammatory NLRP3-RXR axis in asthma. *J Biol Chem*. 2018;293:18454–65.

181. Kim JK, Jin HS, Suh H, Jo E. Negative regulators and their mechanisms in NLRP3 inflammasome activation and signaling. *Immunol Cell Biol*. 2017;95:584–92.

182. Freeman TL, Swartz TH. Targeting the NLRP3 Inflammasome in Severe COVID-19. *Front Immunol*. 2020;11:1518.

183. van den Berg DF, Te Velde AA. Severe COVID-19: NLRP3 Inflammasome Dysregulated. *Front Immunol*. 2020;11:1580.

184. Ratajczak MZ, Kucia M. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells. *Leukemia*. 2020;34:1726–9.

185. Siu K-L, Yuen K-S, Castaño-Rodríguez C, Ye Z-W, Yeung M-L, Fung S-Y, et al. Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. *FASEB J Off Publ Fed Am Soc Exp Biol*. 2019;33:8865–77.

186. Nieto-Torres JL, Verdiá-Báguena C, Jimenez-Guardeño JM, Regla-Nava JA, Castaño-Rodríguez C, Fernandez-Delgado R, et al. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. *Virology*. 2015;485:330–9.

187. Castaño-Rodríguez C, Honrubia JM, Gutiérrez-Álvarez J, DeDiego ML, Nieto-Torres JL, Jimenez-Guardeño JM, et al. Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis. Denison MR, editor. *mBio*. 2018;9:e02325-17, /mbio/9/3/mBio.02325-17.atom.

188. Verdiá-Báguena C, Nieto-Torres JL, Alcaraz A, DeDiego ML, Torres J, Aguilera VM, et al. Coronavirus E protein forms ion channels with functionally and structurally-involved

membrane lipids. *Virology*. 2012;432:485–94.

189. Wagener FADTG, Pickkers P, Peterson SJ, Immenschuh S, Abraham NG. Targeting the Heme-Heme Oxygenase System to Prevent Severe Complications Following COVID-19 Infections. *Antioxidants*. 2020;9:540.

190. Fakhouri EW, Peterson SJ, Kothari J, Alex R, Shapiro JI, Abraham NG. Genetic Polymorphisms Complicate COVID-19 Therapy: Pivotal Role of HO-1 in Cytokine Storm. *Antioxidants*. 2020;9:636.

191. Wei Q, Hill WD, Su Y, Huang S, Dong Z. Heme oxygenase-1 induction contributes to renoprotection by G-CSF during rhabdomyolysis-associated acute kidney injury. *Am J Physiol-Ren Physiol*. 2011;301:F162–70.

192. Chen-Roetling J, Regan RF. Targeting the Nrf2-Heme Oxygenase-1 Axis after Intracerebral Hemorrhage. *Curr Pharm Des*. 2017;23:2226–37.

193. Nurmi K, Kareinen I, Virkanen J, Rajamäki K, Kouri V-P, Vaali K, et al. Hemin and Cobalt Protoporphyrin Inhibit NLRP3 Inflammasome Activation by Enhancing Autophagy: A Novel Mechanism of Inflammasome Regulation. *J Innate Immun*. 2017;9:65–82.

194. Murakami Y, Hoshi M, Imamura Y, Arioka Y, Yamamoto Y, Saito K. Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: potential role in macrophage-mediated inflammatory diseases. *Mediators Inflamm*. 2013;2013:391984.

195. Lee S-M, Park HY, Suh Y-S, Yoon EH, Kim J, Jang WH, et al. Inhibition of acute lethal pulmonary inflammation by the IDO-AhR pathway. *Proc Natl Acad Sci U S A*. 2017;114:E5881–90.

196. Oh G-S, Pae H-O, Choi B-M, Chae S-C, Lee H-S, Ryu D-G, et al. 3-Hydroxyanthranilic acid, one of metabolites of tryptophan via indoleamine 2,3-dioxygenase pathway, suppresses inducible nitric oxide synthase expression by enhancing heme oxygenase-1 expression. *Biochem Biophys Res Commun*. 2004;320:1156–62.

197. Thomas SR, Mohr D, Stocker R. Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. *J Biol Chem*. 1994;269:14457–64.

198. Su Y, Chen D, Lausted C, Yuan D, Choi J, Dai C, et al. Multiomic Immunophenotyping of COVID-19 Patients Reveals Early Infection Trajectories [Internet]. *Immunology*; 2020 Jul. Available from: <http://biorxiv.org/lookup/doi/10.1101/2020.07.27.224063>

199. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T

cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. *Immunity*. 2005;22:633–42.

200. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. *Trends Immunol*. 2013;34:137–43.

201. Stone TW, Stoy N, Darlington LG. An expanding range of targets for kynurenine metabolites of tryptophan. *Trends Pharmacol Sci*. 2013;34:136–43.

202. Hill M, Tanguy-Royer S, Royer P, Chauveau C, Asghar K, Tesson L, et al. IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. *Eur J Immunol*. 2007;37:3054–62.

203. Terness P, Bauer TM, Röse L, Dufter C, Watzlik A, Simon H, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. *J Exp Med*. 2002;196:447–57.

204. Hiramatsu R, Hara T, Akimoto H, Takikawa O, Kawabe T, Isobe K-I, et al. Cinnabarinic acid generated from 3-hydroxyanthranilic acid strongly induces apoptosis in thymocytes through the generation of reactive oxygen species and the induction of caspase. *J Cell Biochem*. 2008;103:42–53.

205. Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. *Proc Natl Acad Sci U S A*. 2010;107:19961–6.

206. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2020;71:762–8.

207. Garman SC, Garboczi DN. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. *J Mol Biol*. 2004;337:319–35.

208. Du J, Zhou Y, Su X, Yu JJ, Khan S, Jiang H, et al. Sirt5 Is a NAD-Dependent Protein Lysine Demalonylase and Desuccinylase. *Science*. 2011;334:806–9.

209. Yang X, Wang Z, Li X, Liu B, Liu M, Liu L, et al. SHMT2 Desuccinylation by SIRT5 Drives Cancer Cell Proliferation. *Cancer Res*. 2018;78:372–86.

210. Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CFW, Steegborn C. Substrates and Regulation Mechanisms for the Human Mitochondrial Sirtuins Sirt3 and Sirt5. *J Mol Biol*. 2008;382:790–801.

211. Keppeke GD, Chang CC, Peng M, Chen L-Y, Lin W-C, Pai L-M, et al. IMP/GTP balance

modulates cytoophidium assembly and IMPDH activity. *Cell Div.* 2018;13:5.

212. Renz A, Widerspick L, Dräger A. FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2. Zenodo; 2020 [cited 2020 Oct 22]; Available from: <https://zenodo.org/record/3752641>

213. Oh J, O'Connor PW. Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects. *Ther Adv Neurol Disord.* 2014;7:239–52.

214. Hayek S, Pietrancosta N, Hovhannisyan AA, Alves de Sousa R, Bekaddour N, Ermellino L, et al. Cerpegin-derived furo[3,4-c]pyridine-3,4(1H,5H)-diones enhance cellular response to interferons by de novo pyrimidine biosynthesis inhibition. *Eur J Med Chem.* 2020;186:111855.

215. Xiong R, Zhang L, Li S, Sun Y, Ding M, Wang Y, et al. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. *Protein Cell.* 2020;11:723–39.

216. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine.* 2020;55:102763.

217. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell Mol Immunol.* 2020;17:533–5.

218. Tan M, Liu Y, Zhou R, Deng X, Li F, Liang K, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. *Immunology.* 2020;160:261–8.

219. Ni L, Ye F, Cheng M-L, Feng Y, Deng Y-Q, Zhao H, et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. *Immunity.* 2020;52:971-977.e3.

220. Bortolotti D, Gentili V, Rizzo S, Rotola A, Rizzo R. SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway. *Cells.* 2020;9.

221. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med.* 2020;8:420–2.

222. Ciccullo A, Borghetti A, Zileri Dal Verme L, Tosoni A, Lombardi F, Garcovich M, et al. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. *Int J Antimicrob Agents.* 2020;56:106017.

223. Kong M, Zhang H, Cao X, Mao X, Lu Z. Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. *Epidemiol Infect.* 2020;148:e139.

224. Zhang Y-Y, Li B-R, Ning B-T. The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections. *Front Immunol.* 2020;11:2033.
225. Guan W-J, Liang W-H, Zhao Y, Liang H-R, Chen Z-S, Li Y-M, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J.* 2020;55.
226. Liu D, Cui P, Zeng S, Wang S, Feng X, Xu S, et al. Risk factors for developing into critical COVID-19 patients in Wuhan, China: A multicenter, retrospective, cohort study. *EClinicalMedicine.* 2020;25:100471.
227. Salimi S, Hamlyn JM. COVID-19 and Crosstalk With the Hallmarks of Aging. *J Gerontol A Biol Sci Med Sci.* 2020;75:e34–41.
228. Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2020;
229. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. *Nat Rev Immunol.* 2020;20:442–7.
230. Collin J, Byström E, Carnahan A, Ahrne M. Public Health Agency of Sweden's Brief Report: Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection in intensive care in Sweden. *Acta Obstet Gynecol Scand.* 2020;99:819–22.
231. Nguyen LH, Drew DA, Graham MS, Joshi AD, Guo C-G, Ma W, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. *Lancet Public Health.* 2020;5:e475–83.
232. Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2020;
233. Li J, Wang X, Chen J, Cai Y, Deng A, Yang M. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. *Br J Haematol.* 2020;190:24–7.
234. Wu Y, Feng Z, Li P, Yu Q. Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19. *Clin Chim Acta Int J Clin Chem.* 2020;509:220–3.
235. Severe Covid-19 GWAS Group, Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *N Engl J Med.* 2020;383:1522–34.
236. Zaidi FZ, Zaidi ARZ, Abdullah SM, Zaidi SZA. COVID-19 and the ABO blood group connection. *Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis.*

2020;102838.

237. O'Sullivan JM, Ward S, Fogarty H, O'Donnell JS. More on "Association between ABO blood groups and risk of SARS-CoV-2 pneumonia." *Br J Haematol.* 2020;190:27-8.

238. Dai X. ABO blood group predisposes to COVID-19 severity and cardiovascular diseases. *Eur J Prev Cardiol.* 2020;27:1436-7.

239. Guillon P, Clément M, Sébille V, Rivain J-G, Chou C-F, Ruvoën-Clouet N, et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. *Glycobiology.* 2008;18:1085-93.

240. Gérard C, Maggipinto G, Minon J-M. COVID-19 and ABO blood group: another viewpoint. *Br J Haematol.* 2020;190:e93-4.

241. Abrams EM, 't Jong GW, Yang CL. Asthma and COVID-19. *CMAJ Can Med Assoc J J Assoc Medicale Can.* 2020;192:E551.

242. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O'Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. *J Allergy Clin Immunol.* 2020;146:203-206.e3.

243. Song J, Zeng M, Wang H, Qin C, Hou H-Y, Sun Z-Y, et al. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. *Allergy.* 2020;

244. Dong X, Cao Y-Y, Lu X-X, Zhang J-J, Du H, Yan Y-Q, et al. Eleven faces of coronavirus disease 2019. *Allergy.* 2020;75:1699-709.

245. Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic. *Clin Rev Allergy Immunol.* 2020;59:78-88.

246. Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, Polverino F, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. *J Allergy Clin Immunol.* 2020;146:80-88.e8.

247. Meftahi GH, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflamm-aging." *Inflamm Res Off J Eur Histamine Res Soc Al.* 2020;69:825-39.

248. Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, et al. Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? *Front Immunol.* 2017;8:1960.

249. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-

- metabolic viewpoint for age-related diseases. *Nat Rev Endocrinol*. 2018;14:576–90.
250. Franceschi C, Zaikin A, Gordleeva S, Ivanchenko M, Bonifazi F, Storci G, et al. Inflammaging 2018: An update and a model. *Semin Immunol*. 2018;40:1–5.
251. Aiello F, Gallo Afflitto G, Mancino R, Li J-PO, Cesareo M, Giannini C, et al. Coronavirus disease 2019 (SARS-CoV-2) and colonization of ocular tissues and secretions: a systematic review. *Eye Lond Engl*. 2020;34:1206–11.
252. Ventura MT, Casciaro M, Gangemi S, Buquicchio R. Immunosenescence in aging: between immune cells depletion and cytokines up-regulation. *Clin Mol Allergy CMA*. 2017;15:21.
253. Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. *BMJ*. 2020;370:m3249.
254. Pierce CA, Preston-Hurlburt P, Dai Y, Aschner CB, Cheshenko N, Galen B, et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. *Sci Transl Med*. 2020;12.
255. Dhochak N, Singhal T, Kabra SK, Lodha R. Pathophysiology of COVID-19: Why Children Fare Better than Adults? *Indian J Pediatr*. 2020;87:537–46.
256. Mehta NS, Mytton OT, Mullins EWS, Fowler TA, Falconer CL, Murphy OB, et al. SARS-CoV-2 (COVID-19): What do we know about children? A systematic review. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2020;
257. Liguoro I, Pilotto C, Bonanni M, Ferrari ME, Pusiol A, Nocerino A, et al. SARS-COV-2 infection in children and newborns: a systematic review. *Eur J Pediatr*. 2020;179:1029–46.
258. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet Lond Engl*. 2020;395:1771–8.
259. Chiotos K, Bassiri H, Behrens EM, Blatz AM, Chang J, Diorio C, et al. Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series. *J Pediatr Infect Dis Soc*. 2020;9:393–8.
260. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet Lond Engl*. 2020;395:1607–8.
261. Levin M. Childhood Multisystem Inflammatory Syndrome - A New Challenge in the

Pandemic. *N Engl J Med.* 2020;383:393–5.

262. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. *N Engl J Med.* 2020;383:334–46.

263. Li Q, Cao Z, Rahman P. Genetic variability of human angiotensin-converting enzyme 2 (hACE2) among various ethnic populations. *Mol Genet Genomic Med.* 2020;8:e1344.

264. Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males? *Int J Mol Sci.* 2020;21.

265. Devaux CA, Rolain J-M, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. *J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi.* 2020;53:425–35.

266. Debnath M, Banerjee M, Berk M. Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes. *FASEB J Off Publ Fed Am Soc Exp Biol.* 2020;34:8787–95.

267. Englmeier L. A theory on SARS-COV-2 susceptibility: reduced TLR7-activity as a mechanistic link between men, obese and elderly. *J Biol Regul Homeost Agents.* 2020;34.

268. Schulte-Schrepping J, Reusch N, Paclik D, Baßler K, Schlickeiser S, Zhang B, et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. *Cell.* 2020;182:1419-1440.e23.

269. Carter-Timofte ME, Jørgensen SE, Freytag MR, Thomsen MM, Brinck Andersen N-S, Al-Mousawi A, et al. Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. *Front Immunol.* 2020;11:1606.

270. Bae J-S, Park J-M, Lee J, Oh B-C, Jang S-H, Lee YB, et al. Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice. *Metabolism.* 2017;66:32–44.

271. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. *Nutrients.* 2020;12.

272. Sharifi A, Vahedi H, Nedjat S, Rafiei H, Hosseinzadeh-Attar MJ. Effect of single-dose injection of vitamin D on immune cytokines in ulcerative colitis patients: a randomized placebo-controlled trial. *APMIS Acta Pathol Microbiol Immunol Scand.* 2019;127:681–7.

273. Gordon CM, Feldman HA, Sinclair L, Williams AL, Kleinman PK, Perez-Rossello J, et al. Prevalence of vitamin D deficiency among healthy infants and toddlers. *Arch Pediatr Adolesc Med.* 2008;162:505–12.
274. Sajuthi SP, DeFord P, Jackson ND, Montgomery MT, Everman JL, Rios CL, et al. Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium. *BioRxiv Prepr Serv Biol.* 2020;
275. De Meulder B, Lefaudeux D, Bansal AT, Mazein A, Chaiboonchoe A, Ahmed H, et al. A computational framework for complex disease stratification from multiple large-scale datasets. *BMC Syst Biol.* 2018;12:60.
276. Li C-X, Wheelock CE, Sköld CM, Wheelock ÅM. Integration of multi-omics datasets enables molecular classification of COPD. *Eur Respir J.* 2018;51.
277. Wang B, Mezlini AM, Demir F, Fiume M, Tu Z, Brudno M, et al. Similarity network fusion for aggregating data types on a genomic scale. *Nat Methods.* 2014;11:333–7.
278. Shen R, Olshen AB, Ladanyi M. Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. *Bioinforma Oxf Engl.* 2009;25:2906–12.
279. Singh A, Shannon CP, Gautier B, Rohart F, Vacher M, Tebbutt SJ, et al. DIABLO: an integrative approach for identifying key molecular drivers from multi-omics assays. *Bioinforma Oxf Engl.* 2019;35:3055–62.
280. Dugourd A, Saez-Rodriguez J. Footprint-based functional analysis of multiomic data. *Curr Opin Syst Biol.* 2019;15:82–90.
281. Bouhaddou M, Memon D, Meyer B, White KM, Rezelj VV, Correa Marrero M, et al. The Global Phosphorylation Landscape of SARS-CoV-2 Infection. *Cell.* 2020;182:685-712.e19.
282. Treveil A, Sudhakar P, Matthews ZJ, Wrzesiński T, Jones EJ, Brooks J, et al. Regulatory network analysis of Paneth cell and goblet cell enriched gut organoids using transcriptomics approaches. *Mol Omics.* 2020;16:39–58.
283. Garcia-Alonso L, Holland CH, Ibrahim MM, Turei D, Saez-Rodriguez J. Benchmark and integration of resources for the estimation of human transcription factor activities. *Genome Res.* 2019;29:1363–75.
284. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. *Cell Discov.* 2020;6:14.
285. Li J, Guo M, Tian X, Wang X, Yang X, Wu P, et al. Virus-Host Interactome and Proteomic

Survey Reveal Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis. *Med N Y N*. 2020;

286. Stukalov A, Girault V, Grass V, Bergant V, Karayel O, Urban C, et al. Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV [Internet]. *Systems Biology*; 2020 Jun. Available from: <http://biorxiv.org/lookup/doi/10.1101/2020.06.17.156455>

287. Aranda B, Blankenburg H, Kerrien S, Brinkman FSL, Ceol A, Chautard E, et al. PSICQUIC and PSISCORE: accessing and scoring molecular interactions. *Nat Methods*. 2011;8:528–9.

288. Messina F, Giombini E, Agrati C, Vairo F, Ascoli Bartoli T, Al Moghazi S, et al. COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. *J Transl Med*. 2020;18:233.

289. Hidalgo MR, Cubuk C, Amadoz A, Salavert F, Carbonell-Caballero J, Dopazo J. High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes. *Oncotarget*. 2017;8:5160–78.

290. Hernansaiz-Ballesteros RD, Salavert F, Sebastián-León P, Alemán A, Medina I, Dopazo J. Assessing the impact of mutations found in next generation sequencing data over human signaling pathways. *Nucleic Acids Res*. 2015;43:W270-275.

291. Salavert F, Hidalgo MR, Amadoz A, Çubuk C, Medina I, Crespo D, et al. Actionable pathways: interactive discovery of therapeutic targets using signaling pathway models. *Nucleic Acids Res*. 2016;44:W212-216.

292. Liu A, Trairatphisan P, Gjerga E, Didangelos A, Barratt J, Saez-Rodriguez J. From expression footprints to causal pathways: contextualizing large signaling networks with CARNIVAL. *NPJ Syst Biol Appl*. 2019;5:40.

293. Helikar T, Kowal B, McClenathan S, Bruckner M, Rowley T, Madrahimov A, et al. The Cell Collective: Toward an open and collaborative approach to systems biology. *BMC Syst Biol*. 2012;6:96.

294. Osborne JM, Fletcher AG, Pitt-Francis JM, Maini PK, Gavaghan DJ. Comparing individual-based approaches to modelling the self-organization of multicellular tissues. *PLoS Comput Biol*. 2017;13:e1005387.

295. Wang Y, An G, Becker A, Cockrell C, Collier N, Craig M, et al. Rapid community-driven development of a SARS-CoV-2 tissue simulator. *BioRxiv Prepr Serv Biol*. 2020;

296. Letort G, Montagud A, Stoll G, Heiland R, Barillot E, Macklin P, et al. PhysiBoSS: a multi-scale agent-based modelling framework integrating physical dimension and cell signalling.

Bioinforma Oxf Engl. 2019;35:1188–96.

297. Ghaffarizadeh A, Heiland R, Friedman SH, Mumenthaler SM, Macklin P. PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems. *PLoS Comput Biol.* 2018;14:e1005991.

298. Stoll G, Caron B, Viara E, Dugourd A, Zinovyev A, Naldi A, et al. MaBoSS 2.0: an environment for stochastic Boolean modeling. *Bioinforma Oxf Engl.* 2017;33:2226–8.

299. Montagud A, Traynard P, Martignetti L, Bonnet E, Barillot E, Zinovyev A, et al. Conceptual and computational framework for logical modelling of biological networks deregulated in diseases. *Brief Bioinform.* 2019;20:1238–49.

300. Alvarez MJ, Shen Y, Giorgi FM, Lachmann A, Ding BB, Ye BH, et al. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. *Nat Genet.* 2016;48:838–47.

301. Fink K, Grandvaux N. STAT2 and IRF9: Beyond ISGF3. *JAK-STAT.* 2013;2:e27521.

302. Cheon H, Holvey-Bates EG, Schoggins JW, Forster S, Hertzog P, Imanaka N, et al. IFN β -dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. *EMBO J.* 2013;32:2751–63.

303. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinforma Oxf Engl.* 2010;26:139–40.

304. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. *Bioinforma Oxf Engl.* 2003;19:185–93.

305. Li S, Zhang Y, Guan Z, Li H, Ye M, Chen X, et al. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. *Signal Transduct Target Ther.* 2020;5:235.

306. Chauhan D, Bartok E, Gaidt MM, Bock FJ, Herrmann J, Seeger JM, et al. BAX/BAK-Induced Apoptosis Results in Caspase-8-Dependent IL-1 β Maturation in Macrophages. *Cell Rep.* 2018;25:2354-2368.e5.

307. Khan S, Fielding BC, Tan THP, Chou C-F, Shen S, Lim SG, et al. Over-expression of severe acute respiratory syndrome coronavirus 3b protein induces both apoptosis and necrosis in Vero E6 cells. *Virus Res.* 2006;122:20–7.

308. Freeman TC, Raza S, Theocharidis A, Ghazal P. The mEPN scheme: an intuitive and flexible graphical system for rendering biological pathways. *BMC Syst Biol.* 2010;4:65.

309. Livigni A, O'Hara L, Polak ME, Angus T, Wright DW, Smith LB, et al. A graphical and computational modeling platform for biological pathways. *Nat Protoc.* 2018;13:705–22.

310. Wittig U, Rey M, Weidemann A, Kania R, Müller W. SABIO-RK: an updated resource for manually curated biochemical reaction kinetics. *Nucleic Acids Res.* 2018;46:D656–60.